Clinical Study Protocol 
A Randomized, Double -Blind, 
Placebo -Controlled Study of COR388 HCl in 
Subjects with Alzheimerâ€™s  Disease  
Protocol Number: COR388 -[ADDRESS_32668] Number: 2019 -000370 -27   
 
 
  
[STUDY_ID_REMOVED]  
 
 
Date  17 May 2021  
 
Protocol COR388-010  Version 7.0 Page 1 
17 May 2021  
Cortexyme, Inc.  Confidential Information CORTEXYME , INC. 
Clinical Study Protocol 
A Randomized, Double-Blind, 
Placebo-Controlled Study of COR388 HCl in 
Subjects with Alzheimerâ€™s Disease  
Protocol Number: COR388-[ADDRESS_32669] Number: 2019-000370-27   
Original Protocol Date (Version):  18 January 2019 (Version 1.0) 
Amended Protocol Date (Versi on): 11 April 2019 (Version 2.0) 
Amended Protocol Date (Version): 25 June 2019 (Version 3.0) 
Amended Protocol Date (Version): 19 December 2019 (Version 4.0) 
Amended Protocol Date (Versi on): [ADDRESS_32670] 2020 (Version 5.0) 
Amended Protocol Date (Version): 15 December 2020 (Version 6.0) 
Amended Protocol Date (Version): 17 May 2021 (Version 7.0) 
Cortexyme, Inc. 
[ADDRESS_32671]. South San Francisco, CA [ZIP_CODE] [EMAIL_517] +[PHONE_526] 
  
Medical Monitor
 Stephen Kirzinger, MD 
Sr. Medical Director 
Worldwide Clinical Trials [ADDRESS_32672] Louisville, KY [ZIP_CODE] Phone: +[PHONE_527]  Email: [EMAIL_518] 
 
  
Protocol COR388-010  Version 7.0 Page 3 
17 May 2021 
Cortexyme, Inc.  Confidential Information Investigatorâ€™s Agreement 
 
I have read Protocol COR388-[ADDRESS_32673] the study according to its terms. I understand that all information supplied to me by [CONTACT_33303], Inc., is confidential.   
 
  
                      
Principal Investigator [INVESTIGATOR_33267] 
    
  
    
3URWRFRO&259HUVLRQ 3DJH
0D\
&RUWH[\PH,QF &RQILGHQWLDO,QIRUPDWLRQ3URWRFRO6LJQDWXUH6KHHW

$5DQGRPL]HG'RXEOH%OLQG
3ODFHER&RQWUROOHG6WXG\RI&25+&OLQ
6XEMHFWVZLWK$O]KHLPHUÂ¶V'LVHDVH 
3URWRFRO1XPEHU&25
(XGUD&71XPEHU
2ULJLQDO3URWRFRO'DWH-DQXDU\
3URWRFROY'DWH$SULO
3URWRFROY'DWH-XQH
3URWRFRO'DWHY'DWH'HFHPEHU
3URWRFRO'DWHY'DWH$XJXVW
3URWRFROY'DWH'HFHPEHU
3URWRFROY'DWH0D \
,DSSURYHWKLV3URWRFROLQFOXGLQJDSSHQGLFHV
$SSURYDO6LJQDWXUH6SRQVRU&RPSDQ\     
 0LFKDHO-'HWNH0'3K'  'DWH 
  &KLHI0HGLFDO2IILFHU
&RUWH[\PH,QF
 (DVW*UDQG$YH
 6RXWK6DQ)UDQFLVFR&$
3KRQH
(PDLOPGHWNH#FRUWH[\PHFRP




	




Protocol COR388-010  Version 7.0 Page 5 
17 May 2021 
Cortexyme, Inc.  Confidential Information 1 PROTOCOL SYNOPSIS 
Title A Randomized, Double-Blind, Placebo- Controlled Study of COR388 HCl in 
Subjects with Alzheimerâ€™s Disease 
Objectives The objectives of the study are to:  
ï‚·Assess the efficacy of 2 dose levels of COR388 HCl in Alzheimerâ€™s
disease (AD) subjects; and
ï‚·Assess the safety and tolerability of 2 dose levels of COR388 HCl inAD subjects.
Study Phase Phase 2/3 
Study Design This is a randomized, double-blind,  placebo-controlled study that will 
assess the efficacy, safety, and tolerability of 2 dose levels of 
COR388 HCl in subjects with probable AD dementia according to the 
National Institute on Aging-Alzheimerâ€™s Association (NIA-AA) criteria 
(McKhann 2011). The study will enroll approximately 573 generally healthy 
male and female subjects ï‚³55 and ï‚£[ADDRESS_32674] year. Clinical decline 
will be defined as
 the evidence of progressive cogniti ve decline on 
sequential evaluations based  on information from informants and/or 
cognitive testing in the context of either formal neuropsychological 
evaluation or standardized mental status examin ations for probabl e AD 
dementia (McKhann 2011). The subject should not have other conditions 
or
 brain imaging abnormalities that can explain the symptoms  of dementia. 
All subjects will have lumbar punctures (LPs) performed at baseline 
(Visit
 2) and at end of treatment Week 48 (Visit 10) or early termination 
visit (ET). Cerebrospi[INVESTIGATOR_872] (CSF) will be tested for measurement of 
bacterial DN
A (Pg) using quantitative polymerase chain reaction (qPCR), 
biomarkers of AD, and gingipain activity.  Saliva, and blood will be 
analyzed for
 biomarkers of AD and neur oinflammation, and for the 
presence of bacterial deoxyribonucle ic acid (DNA) of Porphyromonas 
gingivalis  (P. gingivalis [Pg]) using qPCR.  
A
 subset of sites will be selected to monitor subjects for clinical evidence 
of
 periodontitis in addition to AD. An oral examination will be conducted by 
a study dentist/hygienist at these sites to assess for the presence of 
clinical evidence of periodontiti s at screening, 24 and 48 weeks. 
Subgingival plaque (SGP) and buccal cell swabs will be collected at these 
sites 
and analyzed for measurements of biomarkers associated with 
P. gingivalis  DNA, proteins, and inflammation.
Protocol COR388-[ADDRESS_32675] sign a caregiver informed con sent.  
The safety of study participants will be evaluated throughout the study by 
[CONTACT_33304], vital signs, safety lab o ratory tests,12-lead 
electrocardiograms (E CG s), Columbia-Suicide Seve rit y Ratin g Scal e 
(C-SSRS), magnetic resonance imaging (MRI), and assessments of 
treatment-emergent advers e events (T E AEs). Periodic safety reviews will 
be conducted during the study.  
Following the Data Monitoring Committee (DMC ) recommend ation after 
the November 16, 2020 meeting, increased frequency of liver safe ty 
monitoring has been implemented, which increased the frequency of 
safety laboratory analyte collections (see Table 1 and Table 2, Schedule 
of Evaluations).    
The stud y will consist of 3 periods: a screening peri od of up to 6 weeks, a 
treatment period of up to 48 weeks, and a safety follow-up pe riod of 
6 weeks. An interim analysis may be conducted to reassess the sample 
size and e
valuate for efficacy after 24 weeks of treatment on ke y outcome 
measures. 
Screening 
During the screening period, the eligib ility of subjects will be confirmed 
according to the Sche dule of Evaluations in this protocol. The Mini-Mental 
State Examination (MMSE) will be administered by a trained rater to 
assess the level of cognitive impairment. MMSE will be assessed as early 
in the screening period as possibl e. Subjects with MMSE score of 12-24, 
inclusive, will have the rest of thei r screening procedures performed or 
scheduled. Magnetic resonance im aging (MRI) of the brain will be 
performed in all subjects at screening, except subjects with an absolute 
contraindication for MRI, who can ha ve a Comp uted Tomograp hy (CT) 
scan of the brain instead. Screening procedures can be done on mu ltiple 
days if needed, with more invasive procedures d one after less invasive 
screening procedures a r e completed. A screen failure is an y subject who 
signs the info rmed consent but does not qualify for the study or 
discontinues the study prior to randomization. A subject can be rescreened 
if the Principal Investigator [INVESTIGATOR_33268], and if the Medical Monitor agrees.  
Treatment P
eriod 
Subjects who meet all eligibility crit eria will enter the treatment period and 
will be randomized 1:1:[ADDRESS_32676]
acebo twice a day. Randomization will be stratified by [CONTACT_33305] (MMSE Â• 12 and Â” 18, and MMSE Â• 19 and Â” 24) and 
Apolipoprotein E (ApoE4 positive either homozygou s or heterozygous vs. 
all others) g
enotype to assure balan ced distribution of mild and moderate 
AD and a bal
anced distribution of ApoE4 subjects, across treatment arms. 
Subjects  will receive their assigned b linded study treat ment orally twice a 
day for up to [ADDRESS_32677] a phone call to assess safety at 
Weeks 49 and 51 and will return for the Safety Follow-up Visit (Week 54). 
For subjec ts with early termination, end of study proc edures (Week 48) will 
be performed, and subjects will be encour aged to return to the clinic for 
the Safety Fo llow-up Visit after 6 wee ks. Phone call s will be performed to 
asse ss safety at Week 1 and We ek 3 after end of study proc edures are 
perfo
rmed. 
Open Label Extension 
The open label extension (OLE), as described below, was implemented in 
pro
tocol versi ons 4.0 through 6.0. On 16 Febru ary 2021, the Spons or 
termina
ted the OLE portion of the study following notification from the 
Food an d Dru g Administration (FDA) of a partial clinica l hold. Per this 
notification, n o new patient s were enroll ed into OLE, and all active 
participants were discontinued from study treatment with a requirement 
that
 a follow-up visit occur [ADDRESS_32678] 2 phone calls to 
asse ss 
safety at Week 9 7 and Wee k 98 and  will return for the Safety 
Follow-up Visit at Week 102. 
For
 subjec ts with early termination, end of study proc edures (Week 96) will 
be performed, and subjects will be encour aged to participate in  the Safety 
Follow-u p phone calls an d return to the clinic for Safety Follow-up Visit.  
Study Population The study will enroll approximately 573 generally healthy male and female 
subjects, ï‚³ 55 and ï‚£[ADDRESS_32679] year as defined in the study protocol. 
Criteria for Inclusion 
& Exclusion Investigators should contact [CONTACT_33306]. 
Inclusion Criteria:  
Protocol COR388-010  Version 7.0 Page 8 
17 May 2021 
Cortexyme, Inc.  Confidential Information Subjects will be eligible to participate in  this study if they meet all of the 
following criteria: 
Subject has provided full written informed consent prior to the
performance of any protocol-specified procedure; or if unable to
provide informed consent due to cognitive status, subject has
provided assent and a legally authorized representativ e has
provided 
full written informed consent on behalf of the subject.
Caregiver has provided full
 written informed consent, on a
separate informed consent form (ICF), on his/her 
own behalf prior
to the performance of any protocol-specified procedure.
Male and female subjects must be 55 years to 80 years of age, at
the time of consent.
Subject has probable AD dementia according to the NIA-AA
criteria (
McKhann 2011) with clinical evidence of progressive
cognitive decline in the last year. Clinical decline will be
determined based on serial cognitive test scores, if available, or
subject/caregiver 
report as documented by [CONTACT_737].
Subject has an MMSE score between 12 and 24 inclusive at both 
screening and Visit 2 and a  Â”3-point difference between these
visits.
Subject has a Modified Hachinski score â‰¤4 at screening.
Subject has brain MRI scan
 consistent with the diagnosis  of AD
performed during the screening pe
riod. Computed Tomography
scan can be used only if the subject has an absolute
contraindicati
on for MRI.
Subject has a primary caregiver willing to accept responsibility for
supervising 
the treatment (e.g., administering study drug),
accompanying the study subject to clinic visits and assessing the
condition of the subject throughout the study in accordance with all
protocol requirements.
Subject is not likely to experience a change in living conditions
(e.g., institutionaliz
ation, moving to a different city, etc.), or change
in primary caregiver, during participation in the trial.
Subjects with background symptomatic therapy with
acetylcholinesterase inhibitors, and/or memantine, are allowed as
long as
 the dose has been stable for 90 days prior to screening 
and no changes are planned during the study.
Subjects who have occasional use of sedative agents are
acceptable
, but these agents should not be given within 48 hours
prior to cognitive assessments.
Subjects who have background medications used for stable
chronic illnesses that are not prohibited by [CONTACT_33307]
allowed. The 
dose of psychoactive drugs must be stable for
[ADDRESS_32680] be planned
during the study unless for
 safety reasons.
Subject has body mass index <38 kg/m2 
at Screening.
Subject must be able to ingest oral medications and can swallow
the study drug
 without breaking or crushing.
Protocol COR388-[ADDRESS_32681] be willing to undergo Apolipoprotein E g enotype
(ApoE) g enetic testing (ApoE results may be disclosed after trial
completion).
16.Subjects participating in the study must meet one of the followi ng
criteria:
a.Females: Surgically steriliz ed (e.g., hysterectomy , bilateral
ooph orectomy or tubal ligation) for at least 6 months or
postmenopausal (postmenopausal females mu st have no
menstrual bleeding for at least 1 year). If not
postme nopausal, agree to use a highly effective me thod of
contraception  that can achieve a failure rate of less th an
1% pe r year when used consistently and correc tly, such
as ho rmonal contraception or a double barrier method
(e.g., intrauterine device plus condom or true abstinen ce
defined a s in line with the preferred and usual lifestyle  of
the subj ect. Periodic abstinence e.g. calendar, ovul ation,
symptothe rmal, post-ovulation method s are not
accepta ble. Declaration of abs tinence for the duration  of a
trial, and withdrawal are not acceptable methods of
contraception ) from [ADDRESS_32682] negative human chorioni c
gona dotropin ( È•-hCG) test for pregnancy at screeni ng.
b.Males who have not had a vasectomy must us e
approp riate contraception methods (barrier or  true
abstin ence defined as in line with the preferred and us ual
lifestyle of the  subject. Periodic abstinence e.g. calen dar,
ovulation, symptothermal, pos t-ovulation methods are not
accepta ble. Declaration of abs tinence for the duration  of a
trial, and with drawal are not acceptable method s of
contraception ) from 30 days prior to dosing until 90 da ys
after las t dose.
Open Lab el Extension:  Subjects will be eligible to participate in the open 
label extension portion of the study if they  meet inclusion criteria # 8, 9, 10, 
11, 12, 14, and [ADDRESS_32683] igatorâ€™s opi[INVESTIGATOR_33269]â€™s risk of 
participating in the study or confou nding study assessment should not 
continue in the open label extension portion of the study. The Investigator should contact [CONTACT_13099] r with questions of elig ibility for participation. 
NOTE: Effective 16 February 2021, the OLE portion of the study was 
terminated by [CONTACT_1034].  
Exclusion Criteria:  
Subjects will not be eligible to participate  in this study if they meet any of 
the following exclusion criteria: 
1.Subject has imaging consistent with other differe ntial dementia
diagn oses other than the diagnosis of AD. For exam ple, any
suggestion of vascular disease including multiple infarction
involving large blood vessels or localized single infarction (angul ar
gyrus, thala mus, anterior cerebral artery and posterior cere bral
artery region ), multiple lacunae of the basal nuclei or  white matter
or exte nsive lesions of the periventricular white matte r or
combination of several lesions are considered exclusionar
y.
Protocol COR388-[ADDRESS_32684] 
cognition such as the hippocamp us will also be  exclusionary. 
Finally, Probable CAA with/without supporting pathological 
evidence according to the modified [LOCATION_011] criteria, if in the opi[INVESTIGATOR_33270], would be exclusionary.   Importantly, should there be 
any evidence of neurologic symptoms between scanning and baseline visits, rescanning is neces sary to ensure proper patient 
selection. 
2.Subject has had an increase or  restoration of cognitio n based on
medical histo ry.
3.Subjects who meet the following imaging exclusion criteria will not
be incl uded in this stud y:
a.Claustrophobia that will result in significant anxiety  and
difficulty lyi ng still for brain imaging (MRI or CT scan).
b.Severe motor problems or chronic pain indication that
prevents the subject from lying still for brain imaging.
4.Subject with history of cancer re quiring systemic therapy in the la st
5 yea rs; except for localized cancer of the skin and in-situ ce rvical
cancer successfully treated with surgical excision.  Stable (for at
least 90 days) prostate cancer is allowed.
5.Subject has a contraindication for LP, such as infected ski n over
the needl e entry site, possible increased intracranial pressu re,
severe thrombocytopenia or coagulopathy, suspected spin al
epi[INVESTIGATOR_33271], or spi[INVESTIGATOR_33272] .
6.Subject has evidence of clinically significant unsta ble
cardio vascular, pulmonary, renal, hepatic, gastrointesti nal,
neurologi c or metabolic disease within [ADDRESS_32685] has any of the follo wing cardiovascular conditions:
a.Unstable angina, uncompe nsated and/or sym ptomatic
congestive heart failure (Grade 2 or higher on the Ne w
York Heart Association scale) or myocardial infarction
within 6 months.
b. Acute or poorly controlled blood pressure >180 mmHg
systoli c or >100 mmHg dias tolic.
c.Current, or recent history of, any of the following that are
clinically significant in the investigator's judgment:
arrhythmia, hypotension, heart block (1st, 2nd or 3rd degree
AV block), ANY bundle branch block, ventricular pacing,
symptomatic ectopy,  unstable arrhythmias including atrial
fibrillation; stable atrial fibrillation is allowed.
d.History of prolonged QT or prolonged QT on screening
ECG (QTcF ï‚³480 msec).
e.History of prolonged PR interval or prolonged PR inte rval
on scre ening ECG (PR >210 msec).
Protocol COR388-010  Version 7.0 Page 11 
17 May 2021 
Cortexyme, Inc.  Confidential Information f.History of prolonged QRS interval or prolonge d QRS
interval on screeni ng ECG (QRS >120 msec ).
g. Supraventricular or ventricular ectopy on the screening
ECG or Brugada pattern on the ECG.
8.Subject with major stroke, uncont rolled seizure disorder, or othe r
medical illnesses that in the Invest igatorâ€™s opi[INVESTIGATOR_33273]â€™s risk of participation in the study or confound stud y
assessments.
9.Subject with history or current evidence of major neurologi cal or
psychiatri c illness such as schi zophrenia, bipolar disorder ,
Parkinsonâ€™s Disease, etc. Subjects with major depressive
disorder that may interfere with the patientâ€™s ability to perform the
study and all assessments. NOTE: Mild depression or depres sive
mood a rising in the context of AD are not criteria for exclusi on.
The use of an ti-depressants or t he use of anti-epi[INVESTIGATOR_33274] -seizure-related treatment is allowed if the dose  has
remai ned stable for at least [ADDRESS_32686] with history of violent or aggressive behavio r that requires
medication to  control.
11. Subjects with active suicidal thoughts (Type 4 or 5 on the
C-SSRS ) in the 6 months preceding screening or at baseli ne; or
have a histo ry of a suicide attempt in the previous 2 years, or more
than 1 lifetime suicide attempt; or are at serious suici de risk in the
Investigatorâ€™s clinical judg ment.
12.Subject with history of alcohol  or drug use disorder within
[ADDRESS_32687] has participated in anot her Investigational New Drug (I ND)
resea rch study involving small molecule drugs within [ADDRESS_32688] has any of the following laboratory findings at screening:
a.Alanine aminotransferase >3 x uppe r limit of normal
(ULN), aspartate aminotransfera se >[ADDRESS_32689], or history of
clinically significant liver disease in the Investigatorâ€™s
judgmen t.
NOTE: Subjects with ALT or AST >[ADDRESS_32690] at Visi t
9/Wee k 40 will not be eligible to participat e in OLE.
NOTE: Effective 16 February 2021, the OLE portion  of the
study was terminated by [CONTACT_1034].
b. Hemo globin ï‚£10 g/dl.
Protocol COR388-010  Version 7.0 Page 12 
17 May 2021 
Cortexyme, Inc.  Confidential Information c. International Normalized Ratio (INR) >1.5 or total bilirubin 
>1.[ADDRESS_32691] (unless subject has evidence of Gilbertâ€™s 
disease). 
d. Creatinine clearance (CL) of <45 ml/min. 
e. Poorly controlled diabetes as defined by [CONTACT_33308] A 1C 
(HbA 1C) >8.  
f. Positive blood screen for Human Immunodeficiency Virus 
(HIV 1 and 2), Hepatitis B surface antigen (HBsAg), or 
Hepatitis C virus antibodies (HCV-Ab) at Screening. 
g. Positive urine screen for drugs of abuse that include 
opi[INVESTIGATOR_858], cocaine, amphetamines, or barbiturates.  
17. Subject has abnormal laboratory tests that suggest an alternate 
etiology for dementia, such as serum vitamin B12 deficiency, thyroid function abnormality, severe anemia, electrolyte 
abnormality, or positive syphilis serology. In these cases, the 
patient should be re-evaluated to  determine if these potential 
causes of dementia have been addressed. Only if these causes 
have been ruled out as the cause of the dementia can the patient 
be enrolled.
 
18. Use of systemic (i.e., oral, in travenous, etc., but not topi[INVESTIGATOR_2855]) 
antibiotics in the last 60 days or history of recurrent infection that 
requires chronic or repeated courses of antibiotics.  
 Open Label Extension:  Subjects will not be eligible to participate in open 
label extension portion of the study if they meet any of the following exclusion criteria # 1, 4, 6, 7, 8- 12, 15, 16 a, b, c, d and e. Laboratory 
testing and ECG results from Visit 9 will be used to evaluate eligibility. Subjects with any change in their medica l history that in the Investigatorâ€™s 
opi[INVESTIGATOR_33269]â€™s ri sk of participating in the study or 
confounding study assessment should  not continue in the open label 
extension portion of the study. The Investigator should contact [CONTACT_33309].  
NOTE: Effective 16 February 2021, the OLE portion of the study was 
terminated by [CONTACT_1034]. 
 
Study Treatments Eligible subjects will be randomized 1:1:1 to receive one of the following 
treatments: 
ï‚· 80 mg COR388 HCl, twice daily (bid); 
ï‚· 40 mg COR388 HCl, bid; or 
ï‚· Placebo, bid  
 Open Label Extension: Subjects will receive 40 mg or 80 mg COR388 HCl, 
bid. 
NOTE: Effective [ADDRESS_32692] 
Participation Double-blind:  48 weeks of treatment + up to 6 weeks for screening + 6 
weeks Safety follow up for subjects who donâ€™t participate in open label 
extension 
Open Label Extension:  48 weeks of treatment + 6 weeks for Safety 
follow-up 
NOTE: Effective 16 February 2021, the OLE portion of the study was 
terminated by [CONTACT_1034]. 
Total Duration of Participation:  up to 108 weeks  
Efficacy Evaluations 
The two co-primary endpoints are: 
ï‚· Mean change in Alzheimerâ€™s Di sease Assessment Scale-Cognitive 
Subscale 11 (ADAS-Cog 11) from baseline to the end of treatment 
period.  
ï‚· Mean change in Alzheimerâ€™s Disease Cooperative Study Group-
Activities of Daily Living (ADCS-A DL) from baseline to the end of 
treatment period.  
Secondary endpoints in all subjects include: 
ï‚· Change in Clinical Dementia Rating-Sum of Boxes (CDR-SB). 
ï‚· Change in Mini-Mental State Examination (MMSE) 
ï‚· Change in Neuropsychiatric Inventory (NPI)  
Exploratory endpoints in all participating subjects include change from 
screening/baseline and/or Visit 2 to the end of treatment period in the following measures: 
ï‚·  
ï‚· Blood-based biomarkers in serum and peripheral blood 
mononuclear cells (PBMCs); and 
ï‚· Saliva biomarkers of P. gingivalis  infection and inflammation. 
ï‚· Cerebrospi[INVESTIGATOR_872]: 
o CSF A È•42, total Tau, and phosphorylated Tau; 
o Bacterial DNA in the CSF based on quantitative 
polymerase chain reaction (q PCR) and sequencing; and 
o CSF biomarkers. 
 
 Exploratory endpoints in subjects pa rticipating in sub-studies include 
change from screening/baseline to the end of treatment period in the following measures: 
ï‚· Winterlight Speech Assessment ( only in English speaking (primary 
language) subjects and only in the US and [LOCATION_006]); 
ï‚· Magnetic resonance imaging sub-study (subjects who have MRIs 
done in conjunction with the study): 
o Hippocampal volume; and 
o Cortical thickness. 
 
Protocol COR388-010  Version 7.0 Page 14 
17 May 2021 
Cortexyme, Inc.  Confidential Information  ï‚· Clinical periodontitis sub-study  (subjects enrolled at selected 
sites):  
o Pocket Depth (PD); 
o Clinical Attachment Level (CAL) at 6 sites per tooth 
(distobuccal [DB], buccal [B], mesiobuccal [MB], 
distolingual [DL], lingual [L], and mesiolingual [ML]); 
o The percentage of sites with Bleeding on Probing (BOP); 
and 
o Biomarkers of P. gingivalis infection and inflammation in 
subgingival plaque (SGP) and buccal cell swabs.  
  
Safety Endpoints Safety endpoints include: 
ï‚· The incidence and severity of TEAEs; 
ï‚· Vital signs and physical examinations; 
ï‚· Laboratory values; 
ï‚· MRI scans; 
ï‚· 12-lead ECGs; and 
ï‚· C-SSRS. 
 Open Label Extension: 
ï‚· The incidence and severity of TEAEs; 
ï‚· Vital signs and physical examinations; 
ï‚· Laboratory values; 
ï‚· 12-lead ECGs; and 
ï‚· C-SSRS. 
NOTE: Effective 16 February 2021, the OLE portion of the study was 
terminated by [CONTACT_1034]. 
Statistical 
Considerations  
The study is designed as an adaptive trial and will allow for stoppi[INVESTIGATOR_33275], futility and potential adjustment in sample size based on the 
results of a planned interim analysis. Approximately 573 subjects are 
planned to be randomized 1:1:1 per treatment group (191 per treatment group) assuming approximately 10% will drop out prior to 48 weeks. This 
sample size would provide approximately 90% power to detect a 2.5-point 
difference between active treatment group and placebo with respect to change from baseline ADAS-Cog [ADDRESS_32693] deviation of 10. 5, providing approximately 95% 
power on this outcome measure, with approximately 90% power for the overall co-primary outcomes, depending on their correlation. 
An unblinded interim analysis will be conducted by a firewalled 
independent statistician (all clinical trial personnel will remain blinded) 
when approximately [ADDRESS_32694] completed the Week 24 visit, then a 
si
gnificance level of 0.005 will be used for the interim anal ysis and a 
Protocol COR388-010  Version 7.0 Page 15 
17 May 2021 
Cortexyme, Inc.  Confidential Information significance level of approximately 0.0456 will be used for the final 
analysis.   
Further details are provided in the statistical analysis plan (SAP). 
 
 
 
Protocol COR388-010  Version 7.0  Page 16 
15 May 2021 
Cortexyme, Inc.    Confidential Information Table 1.  Schedule of Evaluations â€“ Double-blind study  
Study Period Screening Treatment Period Safety Follow-up  
(if not participating in 
open label extension 
portion12) 
Visit number 1 2 3 3a 4 4a 4b 5 5a 6  6a 7 7a 8  9 10/ET12 Phone Call 11 
Week -6 to -1 0 2 4 6 8 10 12 15 18 21 24 28 32 40 48 49 51 54 
Day -42 to -1 0 - 
7 14 
Â± 2 28 
Â± 3 42 
Â± 3 56 
Â± 3 70 
Â± 3 84 
Â± 3 105 
Â± 3 126 
Â± 3 147 
Â± 3 168 
Â± 3 196 
Â± 3 224 
Â± 3 280 
Â± 8 336  
Â± 8 343 
Â± 2 357 
Â± 2 378  
Â± 8 
Evaluations                    
Informed Consent X               X13    
Inclusion/Exclusion Criteria X X              X14    
Medical History and confirmation of 
cognitive decline in the last 12 
months X                    
Full Physical Examination, Height, and BMI Calculation X                    
MRI (or CT) of the Brain X                X1    
Modified Hachinski  X                   
MMSE2 X X      X    X   X X   X 
Randomization  X                   
ADAS-Cog [ADDRESS_32695]-SB X X      X    X   X X   X 
NPI  X          X    X    
Winterlight Speech Assessment (only in English speaking (primary 
language) subjects and only in the 
US and [LOCATION_006]) X X      X    X    X    
Dispense Study Drug   X X  X   X    X   X X15    
Concomitant Medications X X X  X   X  X  X  X X X X X X 
Oral Examination and collection of oral biomarker samples (only at 
selected sites)
3 X            X4    X4,5    
Saliva Collection X X          X    X   X 
Symptom-Based Physical Examination  X X  X   X  X  X  X X X   X 
W e i g h t  X                X     
Vital Signs X X X  X   X  X  X  X X X   X 
Columbia-Suicide Severity Rating Scale X X X  X   X  X  X  X X X   X 
      Footnotes appear on following page. 
Protocol COR388-010  Version 7.0  Page 17 
15 May 2021 
Cortexyme, Inc.    Confidential Information  
 
Table 1.  Schedule of Evaluations  â€“ Double-blind study (Continued) 
 
Study Period Screening Treatment Period Safety Follow-up  
(if not participating 
in open label 
extension portion12) 
Visit numbe r 1 2 3 3a 4 4a 4b 5 5a 6 6a 7 7a 8 9 10/ET12 Phone Call 11 
Week -6 to -1 0 2 4 6 8 10 12 15 18 21 24 28 32 40 48 49 51 54 
Day -42 to -1 0 - 7 14 
Â± 2 28 
Â± 3 42 
Â± 3 56 
Â± 3 70 
Â± 3 84 
Â± 3 105 
Â± 3 126 
Â± 3 147 
Â± 3 168 
Â± 3 196 
Â± 3 224 
Â± 3 280 
Â± 8 336  
Â± 8 343 
Â± 2 357 
Â± 2 378  
Â± 8 
Evaluations                    
Safety Laboratory Tests16 X X X  X   X  X  X  X X X   X 
Liver Safety Monitoring16    X  X X  X  X  X       
Lumbar Puncture (LP)[ADDRESS_32696] X                X     
Blood Collection for FSH11 X                    
Serum and whole blood 
(PBMCs) for biomarkers   X          X    X    
Blood Collection for Serology (HCV-Ab, HBsAg, HIV 1 and 
2) X                    
Blood Collection for Vit. B12, 
Thyroid function tests and 
Syphilis X                    
Urine Collection for Drug 
Screen X  X                   
1. Visit 10/ET MRI will be done only in subjects who had a screening MRI performed and may be done up to 8 days prior to Visit 10/ET. CT scans of the brain 
can be used instead of MRIs, only in subjects who have an absolute contraindication for MRI. 
2. Administer the first MMSE as early in the screening period as possible. MMSE score should be ï‚³12 and ï‚£ 24 at both screening and Visit 2, and a Â”3-point 
difference between visits, for inclusion in the study. 
3. Oral biomarker samples include subgingival plaque and buccal cell swabs (only at selected sites). 
4. Subjects will have follow-up oral examinations at 24 and 48 weeks. 
5. Visit 10/ET oral examinations may be completed up to 8 days prior to Visit 10 (or ET) when applicable. 
6. Baseline (V2) LP must be done after the baseline MMSE score has been verified and subjectâ€™s eligibility has been confirmed, and prior to the first dose of 
study drug. To allow flexibilit y of scheduling the LP procedure, the MMSE and then the LP may be performed up to 7 days prior t o baseline V2.  Likewise, the 
LP at Visit10/ET may be performed up to [ADDRESS_32697] be 
Protocol COR388-010  Version 7.0  Page 18 
15 May 2021 
Cortexyme, Inc.    Confidential Information performed as per SOC and site specific SOPs, if applicable (i ncluding imaging before and/or during the LP, if required).  
7. A pre-dose trough sample will be drawn at  all visits 2, 3, and [ADDRESS_32698] 
while on-site at the clinic per the follow ing schedule: V2 30 minutes - 4 hours; V3 60 minutes Â± 30 minutes; V7 2 hours Â± 30 mi nutes; V9 3 hours Â± 30 minutes; 
and V10/ET 4 hours Â± [ADDRESS_32699] takes their dose of study drug on-site, ECGs should be measured approximately 1-1.5 hours after d osing.  
9. At Visit 3 and Visit 7, ECGs will also be performed at trough (prior to dosing).   
10. A urine pregnancy test will be conducted only in women of child bearing potential at screening and End of Treatment or Earl y Termination Visit 10, and at 
other visits only if indicated. If the urine pregnancy test is positive, a serum pregnancy test will be performed to confirm pr egnancy. 
11. Only for peri-menopausal (irregular menstrual periods) or post-menopausal (no menstrual peri od for >12 months) female subje cts. 
12. Subjects who want to participate in the open label extension portion of the st udy will complete the Week 48 visit and then continue with the Schedule of 
Evaluations in Table 2. NOTE: Effective 16 February 2021, the OLE portion of  the study was terminated by [CONTACT_1034]. 
13. Informed consent will be obtained for subjects who agree to par ticipate in the open label ex tension portion of the study. 
14. Inclusion/exclusion will be evaluated to determine eligibilit y for subjects who want to participate in the open label exten sion portion of the study. Laboratory 
testing and ECG results from Visit [ADDRESS_32700] udy drug (40 mg or 80 mg) will be  dispensed at V10. The subject should 
be instructed to take the first dos e in the morning of the next day. 
16. Liver Safety Monitoring (laboratory analyte testing) must be performed at each study visit within the prespecified visit wi ndow OR the study drug dosing must 
be interrupted until the testing is done.   
Abbreviations: AD = Alzheimerâ€™s Disease; ADAS-Cog 11 = Alzhei merâ€™s Disease Assessment Scale-Cognitive Subscale 11;  
ADCS-ADL = Alzheimerâ€™s Disease Cooperative Study Group-Activities of Daily Living; AM = morning; ApoE = apolipoprotein E; BMI =  body mass index;  
CDR-SB = Clinical Dementia Rating-Sum of Boxes; CSF = cerebrospi [INVESTIGATOR_872]; CT = Computed Tomography; DNA = deoxyribonucleic aci d;  
ECG = electrocardiogram; ET = Early Termination; FSH = Follicle Stimulating Hormone; HBsAg = H epatitis B surface antigen; HCV-Ab = Hepatitis C virus 
antibodies; HIV 1 and 2 = Human Immunodeficiency Virus 1 and 2; MMSE = Mini-Mental  State Examination;  
MRI = magnetic resonance imaging; NPI = Neuropsychiatric Inventory; PBMCs = peripheral blood mononuclear cells; Pg = Porphyromonas gingivalis ;  
PK = pharmacokinetics; qPCR = quantitative polymerase chain reaction. 
 
 
  
Protocol COR388-010  Version 7.0  Page 19 
15 May 2021 
Cortexyme, Inc.    Confidential Information Table 2.  Schedule of Evaluations â€“ Open Label Extension4 
Stud y Period  Treatment Period4 Safet y Follow-up  
Visit number OLE-
1 OLE-
1a OLE-2 OLE-
2a OLE-
2b OLE-3 OLE-
3a OLE-
3b OLE-
3c OLE-4 OLE-
4a OLE-5 OLE-
6/ET OLE-Phone 
Call OLE-9 
       OLE-7 OLE-8 
Week 50 52 54 56 58 60 63 66 69 72 78 84 96 97 98 102 
Day 350 
Â± 3 364 
Â± 3  378 
Â± 3 392 
Â± 3 406 
Â± 3 420 
Â± 3 441 
Â± 3 462 
Â± 3 483 
Â± 3 504 
Â± 3 546 
Â± 6 588 
Â± 6 672  
Â± 8 679 
Â± 2 686 
Â± 2 714  
Â± 8 
Evaluations                 
Informed Consent                 
Inclusion/Exclusion 
Criteria                 
ADAS-Cog [ADDRESS_32701]-SB      X    X   X   X 
Dispense Study Drug  X  X   X    X  X     
Concomitant Medications X  X   X    X  X X X X X 
Saliva Collection          X   X   X 
Symptom-Based 
Physical Examination X  X   X    X  X X   X 
Weight             X    
Vital Signs X  X   X    X  X X   X 
Columbia-Suicide Severity Rating Scale X  X   X    X  X X X X X 
Liver Safety Monitoring3  X  X X  X X X  X      
Safety Laboratory Tests X  X   X    X  X X   X 
Urine pregnancy test1             X     
Adverse Events X  X   X    X  X X X X X 
12-Lead ECG X  X       X   X   X 
Oral Examination and collection of oral 
biomarker samples (only 
at selected sites)
[ADDRESS_32702] will 
be performed to confirm pregnancy. 
2. Oral biomarker samples include subgingival plaque and buccal ce ll swabs (only at selected sites). Visit OLE-6/ET oral examin ations may be 
completed up to 8 days prior to OLE-6 Visit (or ET) when applicable. 
3. Liver Safety Monitoring (laboratory analyte testing) must be performed at each study visit within the prespecified visit window OR the study drug 
dosing must be interrupted until the testing is done.  
4. NOTE: Effective [ADDRESS_32703] Information ............................................................................................... 2 Â 
Investigatorâ€™s Agreement ....................................................................................... [ADDRESS_32704] Restrictions .................................................................................... 38 Â 
6.3.1Â Â  Prior and Concomitant Medications ..................................................... 38 Â 
7Â Â Study Visits ...................................................................................................... 39 Â 
7.1Â  Screening: Visit 1 (Day -42 to Day -1) ......................................................... 39 Â 
7.2Â  Study Treatment: Visit 2 (Day 0) ................................................................. 40 Â 
7.3Â  Study Treatment: Visit 3 (Day 14 Â± 2) ......................................................... 42 Â 
7.4Â  Study Treatment: Visit 4 (Day 42 Â± 3) ......................................................... 42 Â 
7.5Â  Study Treatment: Visit 5 (Day 84 Â± 3) ......................................................... 42 Â 
7.6Â  Study Treatment: Visit 6 (Day 126 Â± 3) ....................................................... 43 Â 
7.7Â  Study Treatment: Visit 7 (Day 168 Â± 3) ....................................................... 43 Â 
7.8Â  Study Treatment: Visit 8 (Day 224 Â± 3) ....................................................... 44 Â 
7.9Â  Study Treatment: Visit 9 (Day 280 Â± 8) ....................................................... 44 Â 
7.10Â Â  Study Treatment: Visit 10/Early Termination (Day 336 Â± 8) ........................ 45 Â 
7.11Â Â  Safety Follow-up Phone Calls: (Days 343 Â± 2 and 357 Â± 2)  ........................ 46 Â 
7.12Â Â  Safety Follow-up Visit: Visit 11 (Day 378 Â± 8) ............................................. 46 Â 
7.13Â Â  Increased Safety Laboratory Monitoring (Liver Safety Monitoring)  ............. 47 Â 
Protocol COR388-010  Version 7.0 Page 21 
17 May 2021 
Cortexyme, Inc.  Confidential Information 7.14Â Â  Open Label Extension (OLE) ...................................................................... 48 Â 
7.15Â Â  OLE Study Treatment: Visit OLE-1 (Day 350 Â± 3) ....................................... 48 Â 
7.16Â Â  OLE Study Treatment: Visit OLE-2 (Day 378 Â± 3) ....................................... 48 Â 
7.17Â Â  OLE Study Treatment: Visit OLE-3 (Day 420 Â± 3)  ....................................... 49 Â 
7.18Â Â  OLE Study Treatment: Visit OLE-4 (Day 504 Â± 3) ....................................... 49 Â 
7.19Â Â  OLE Study Treatment: Visit OLE-5 (Day 588 Â± 6) ....................................... 49 Â 
7.20Â Â  OLE Study Treatment: Visit OLE-6/Early Termination (Day 672 Â± 8) .......... 50 Â 
7.21Â Â  OLE Safety Follow-up Phone Calls: Visits OLE-7 and OLE-8 (Days 679 Â± 2 
and 686 Â± 2) ................................................................................................ 50 Â 
7.22Â Â  Unscheduled Visit(s) ................................................................................... 51 Â 
7.23Â Â  Allowances in the Circumstance of a Public Health Emergency ................. 51 Â 
8Â Â Study Procedures ............................................................................................ 52 Â 
8.1Â  Informed Consent ....................................................................................... 52 Â 
8.2Â  Medical and Medication History .................................................................. 53 Â 
8.3Â  Mini-Mental State Examination (MMSE) ..................................................... 53 Â 
8.4Â  Randomization ............................................................................................ 53 Â 
8.5Â  Dispense Study Drug .................................................................................. 54 Â 
8.6Â  Alzheimerâ€™s Disease Assessment Scale-Cognitive Subscale 11 
(ADAS-Cog 11) ........................................................................................... 54 Â 
8.7Â  Clinical Dementia Rating-Sum of Boxes (CDR-SB) .................................... 54 Â 
8.8Â  Alzheimerâ€™s Disease Cooperative Study Group-Activities of Daily Living 
(ADCS-ADL) ............................................................................................... 55 Â 
8.9Â  Neuropsychiatric Inventory (NPI) ................................................................ 55 Â 
8.10Â Â  Winterlight Speech Assess ment ................................................................. 55 Â 
8.11Â Â  Saliva Collec tion ......................................................................................... 55 Â 
8.12Â Â  Oral Examin ation ........................................................................................ 56 Â 
8.12.1Â Â  Oral Examination Procedures .............................................................. 56 Â 
8.12.2Â Â  Oral Samples Col lecti on ...................................................................... 57 Â 
8.13Â Â  Physical Examination .................................................................................. 58 Â 
8.14Â Â  Brain Imaging .............................................................................................. 58 Â 
8.15Â Â  Modified Hachinski ...................................................................................... 58 Â 
8.16Â Â  Height, Weight, and Body Mass Index (BMI) .............................................. 58 Â 
8.17Â Â  Vital Signs ................................................................................................... 58 Â 
8.18Â Â  Columbia-Suicide Severity Rating Scale (C-SSRS)  .................................... 58 Â 
8.19Â Â  Laboratory Assessments ............................................................................. 59 Â 
8.19.1Â Â  Monitoring of Laboratory Abnormalities ............................................... 60 Â 
8.20Â Â  Urine Drug Screen ...................................................................................... 60 Â 
8.21Â Â  Blood Pharmacokinetic (PK) Evaluations .................................................... 60 Â 
8.22Â Â  Cerebrospi[INVESTIGATOR_17106] (CSF) Evaluations ....................................................... 61 Â 
8.23Â Â  Electrocardiograms (ECGs) ........................................................................ [ADDRESS_32705]/Independent Ethics Committee ......................... [ADDRESS_32706] Privacy .................................................................................... 78 Â 
12.11Â Amendments to the Protocol ................................................................ 78 Â 
12.12Â Case Report Form Completion ............................................................ 78 Â 
12.13Â Removal of Subjects from Therapy or As sessment ............................. 79 Â 
12.14Â End of the Study .................................................................................. 80 Â 
13Â Â References ....................................................................................................... 81 Â 
Appendix A: Clinical Laboratory Analytes .......................................................... [ADDRESS_32707] of Tables 
Table 1. Â Â  Schedule of Evaluations â€“ Double-blind study ........................................ 16 Â 
Table 2. Â Â  Schedule of Evaluations â€“ Open Label Extension .................................. [ADDRESS_32708] of Abbreviations 
Abbreviation Term 
Abnormal CS Abnormal Clinically Significant 
Abnormal NCS Abnormal Not Clinically Significant 
AD Alzheimerâ€™s disease
ADAS-Cog 11 Alzheimerâ€™s Disease Assessm ent Scale-Cognitive Subscale 11 
ADCS-ADL Alzheimerâ€™s Disease Cooperativ e Study Group-Activities of Daily 
Living 
ADR Adverse drug reaction 
AE Adverse event
AL Attachment level
ANCOVA Analysis of covariance 
ApoE Apolipoprotein E
B buccal
Bid Twice daily
BMI Body mass index 
BOP Bleeding on Probing 
CAL Clinical Attachment Level 
CDC/AAP Centers for Disease Contro l/American Academy of 
Periodontology 
CDR-SB Clinical Dementia Rating-Sum of Boxes 
CEJ Cementoenamel junction
CFR Code of Federal Regulations 
CL Creatinine clearance
CNS Central Nervous System 
CRA Clinical Research Associate 
CRO Contract Research Organization 
CS Compound symmetry
CSF Cerebrospi[INVESTIGATOR_33276] 
C-SSRS Columbia-Suicide Severity Rating Scale 
CT Computed Tomography
CV Coefficient of variation 
DB Distobuccal
DL Distolingual
DMC Data Monitoring Committee 
DNA Deoxyribonucleic acid
ECG Electrocardiogram
eCRF Electronic Case Report Form 
Protocol COR388-[ADDRESS_32709]  
HIV Human Immunodeficiency Virus HPMC Hydroxypropyl methylcellulose IB Investigatorâ€™s Brochure 
ICF Informed consent form 
ICH International Conference on Harmonisation  IEC Independent Ethics Committee 
IND Investigational New Drug 
INR International Normalized Ratio IRB Institutional Review Board IRS Interactive Response System 
ITT Intent-to-Treat 
L Lingual LP Lumbar Puncture 
MAR Missing at random 
MB Mesiobuccal MedDRA Medical Dictionary for Regulatory Activities 
ML Mesiolingual 
MMRM Mixed-effects model for repeated measures  
MMSE Mini-Mental State Examination 
MNAR Missing not at random 
MRI Magnetic resonance imaging NIA-AA National Inst itute on Aging-Alzheimerâ€™s Association 
NOAEL No observed adverse effect level NPI [INVESTIGATOR_33277] (P. gingivalis [Pg]) 
PK Pharmacokinetics PP Per Protocol 
PT Preferred Term 
Protocol COR388-[ADDRESS_32710] Upper limit of normal  
  
Protocol COR388-010  Version 7.0 Page 26 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 2 INTRODUCTION 
Alzheimerâ€™s disease (AD) continues to cause a tremendous impact on the lives of 
millions of patients and their caregi vers and puts a huge burden on healthcare 
systems worldwide. In the absence of effe ctive disease modifying treatments, AD 
continues to represent a major area of unmet medical need. Cortexyme is 
developi[INVESTIGATOR_007] a novel small molecule, COR 388 HCl, for the treatment of AD. The 
development of this compound represents a new paradigm for disease modification 
in AD that is based on a large body of em erging scientific data from both Cortexyme 
and independent researchers, as  detailed in the Investi gatorâ€™s Brochure (IB) and 
summarized in the sections below. 
Cortexyme has discovered evidence of Porphyromonas gingivalis  (P. gingivalis [Pg] ) 
in the brains of a large proportion of Al zheimerâ€™s patients compared to controls. 
P. gingivalis  is a Gram-negative asaccharolyt ic pathogen and a keystone bacterium 
in the development of per iodontal disease. Gingipains are cysteine proteases 
produced by [CONTACT_33310], host cell toxicity, and 
immune evasion. P. gingivalis infection has been identified as a risk factor for a 
number of chronic inflammatory disease st ates including AD, atherosclerosis, and 
type [ADDRESS_32711] prevalent age-related ch ronic infection in humans, to diagnosis 
and rapid decline of AD. Cortexyme conducted a series of experiments to evaluate 
the presence of Pg and gingipains in the brains of  AD patients and control groups, 
explore the role of Pg in the pathogenesis of AD, and evaluate gingipains as a 
therapeutic target. Based on the data summari zed in the IB, Cortexyme believes this 
compound will slow or prevent further neurodegeneration, cogniti ve decline, and 
accumulation of pathology in AD patients. 
COR388 HCl is a proprietary small molecu le that is a potent and selective 
irreversible inhibitor of the bacterial  protease lysine gingipain (Kgp) that was 
selected as a lead compound to progress toward human clinical trials based on its 
selectivity, pharmacokinetics (PK), efficacy, and safety profiles.  
A comprehensive program was conducted to assess the PK, safety, and toxicity of COR388 HCl in [ADDRESS_32712] ration, resulting in 
sufficient plasma and central nervous system (CNS) exposures for clinical efficacy. 
COR388 is a chiral molecule whose epi[INVESTIGATOR_33278]490 is produced in vivo and has a 
similar potency, efficacy and PK profile. COR388 has a moderate level of plasma 
protein binding in animal species te sted and human subjects. COR388 is cleared 
rapi[INVESTIGATOR_375], with a terminal half-life ranging from  2-3.[ADDRESS_32713] eady state in humans. 
No evidence of genotoxicity was found on eit her a battery of in vitro studies in 
bacteria and mammalian cells or in an in vivo micronucleus study. General toxicology studies in mice and dogs s howed no change in serum chemistry, 
Protocol COR388-010  Version 7.0 Page 27 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 hematology, and urinalysis la boratory parameters. Treatment with large doses of 
COR388 was associated with transient cardiovascular effects in dogs. 
Histopathology evaluation with light and fluore scent microscopy, as well as electron 
microscopy, revealed minimal increase in the size and number of intracytoplasmic lysosomes in the brain in mice and dogs and the kidney in dogs. There was no evidence of cellular injury. These were considered an adaptive response by [CONTACT_33311]388 and metabolites, 
that may not be expected to occur with the lower exposure levels planned in human trials. These findings were considered non-adverse in dogs at all doses, and in mice 
treated with doses ï‚£100 mg/kg/day. After a 28-day recovery period, a complete 
reversal of the findings was found in the kidneys in dogs and the stratum radiatum in 
mice, with partial recovery in ot her parts of the mouse brain. 
Safety pharmacology studies revealed tr ansient, and reversible effects on the 
cardiovascular and CNS systems. The no obser ved adverse effect levels (NOAELs) 
associated with these effects provide large safety margins over the doses used in 
this trial.  
Cortexyme has completed two Phase 1 safety and PK studies. The Phase 1 
program included a single ascending dose study in normal healthy volunteers, and a 
multiple ascending dose study in older healthy volunteers and AD subjects with 
clinical evidence of periodontitis.   
Results from the single ascending dose study showed that COR388 HCl was 
absorbed rapi[INVESTIGATOR_33279] 25 to 150 mg. Clearance was rapid, with a mean half-life (tÂ½) of [ADDRESS_32714] in the 250 mg dose cohort. 
Treatment-emergent adverse events (TEAEs) were infrequent, mostly mild in severity, and transient. There were no deaths, Serious Adverse Events (SAEs), or TEAEs leading to study drug disconti nuation during the study. There were no 
clinically meaningful changes in safety  laboratory findings, electrocardiograms 
(ECGs), vital signs, or physical exami nations observed during the study.  
The multiple ascending dose study revealed  that oral doses of COR388 HCl ranging 
from 25 to 100 mg every 12 hours were sa fe and well tolerated when administered 
to normal healthy volunteers 55 to 70 years of age and Alzheimerâ€™s disease (AD) subjects 58 to 83 years of age. Subjec ts who received COR388 HCl experienced 
infrequent TEAEs, which were mostly mild in severity and transient. There were no deaths, SAEs, or TEAEs leading to study drug discontinuation during the study. 
There were no clinically meaningful changes  in laboratory param eters, vital signs, 
ECGs, or physical examination findings observed during t he study. COR388 HCl 
was readily bioavailable after oral adminis tration, with good ti ssue distribution and 
Protocol COR388-010  Version 7.0 Page 28 
17 May 2021 
Cortexyme, Inc.  Confidential Information rapid clearance. The results of the Phase 1a/b trials are described in more detail in 
the IB.  
Safety and PK data from the Phase 1 a/b program along with appropriate preclinical 
chronic toxicology and other studies enabled Cortexyme to select appropriate doses 
and move forward with the Phase 2/3 program. 
3 STUDY OBJECTIVES 
The objectives of the study are to:  
ï‚·Assess the efficacy of 2 dose levels of COR388 HCl in Alzheimerâ€™s disease
(AD) subjects; and
ï‚·Assess the safety and tolerability of 2 dose levels of COR388 HCl in AD
subjects.
4 INVESTIGATIONAL PLAN 
4.1 
Overall Study Design and Plan 
This is a randomized, double-blind, placebo-controlled study that will assess the 
efficacy, safety, and tolerability of 2 dos
e levels of COR388 HCl in subjects with 
probable AD dementia according to the National Institute on Aging-Alzheimerâ€™s 
Association (NIA-AA) criteria (McKhann 2011). The study will enroll approximately 
573 generally 
healthy male and female subjects, ï‚³55 and ï‚£[ADDRESS_32715] year. Clinical decline will be 
defined as the evidence of progressive
 cognitive decline on subsequent evaluations 
based on information from informants and/or cogni
tive testing in the context of either 
formal neuropsychological evaluation or standardized mental status examinations for 
probable AD dementia 
(McKhann 2011). The subject should not have other 
conditions or brain imaging abnormality that can explain the symptoms of dementia. 
A Lumbar Puncture (LP) will be performed
 at baseline (Visit 2) and at end of 
treatment period week 48 (Visit 10) or early termination visit (ET). Cerebrospi[INVESTIGATOR_872] 
(CSF) will be tested for measurement of bacterial DNA (Pg) using quantitative 
polymerase chain reaction (qPCR), biom
arkers of AD, and gingipain activity. Saliva, 
and blood will be analyzed for measurements of biomarkers of AD and 
neuroinflammation, 
and for the presence of bacterial deoxyribonucleic acid (DNA) of 
Porphyromonas gingivalis  (P. gingivalis [Pg]) using qPCR.   
A subset of sites will be selected to monitor subjects for clinical evidence of 
periodontitis 
in addition to AD. An oral examination will be conducted by a study 
dentist/hygienist at these sites to assess for the presence of clinical evidence of 
periodontitis. Subjects will have follow-up or al examinations at 24 and 48 weeks. 
Subgingival plaque (SGP) and buccal cell sw
abs will be collected in addition to 
saliva at these sites and analyzed for measurements of biomarkers associated with 
P.
 gingivalis  DNA, proteins, and inflammation.
Protocol COR388-[ADDRESS_32716] sign a caregiver informed consent.  
The safety of study participants will be evaluated throughout the study by [CONTACT_33312], vital signs, safety laboratory tests,12-l ead electrocardiograms 
(ECGs), C
olumbia-Suicide Severity Ra ting Scale (C-SSRS), magnetic resonance 
imaging (MRI), and assessments of treatment -emergent adverse events (TEAEs). 
Periodic safety reviews will be conducted during the study.  
The study will consist of 3 periods: a screeni
ng period of up to 6 weeks, a treatment 
period of up to 48 weeks, and a safety fo llow-up period of 6 weeks. An interim 
analys
is may be conducted to reassess the sample size and evaluate for efficacy 
after 24 weeks of treatment
 on key outcome measures. 
During the screening period, the eligibility of subjects will be confirmed according to 
the Schedule of Evaluations (Table 1). 
Eligible subjects will be randomized 1:1:1 to receive one of the following treatments: 
ï‚·80 mg COR388 HCl, twice daily (bid);
ï‚·40 mg COR388 HCl, bid; or
ï‚·Placebo, bid.
The study drug will be provided in capsule form for oral administration. All capsules 
will be identical in appearance. 
4.1.1 
Scientific Rationale for Study Design 
The primary objective of the study is to assess the efficacy of COR388 HCl in the 
treatment of AD. Based on the postulated mechanism of action of this compound, 
treatment is expected to slow or pr event further neurodegeneration, cognitive 
decline, and accumulation of pathology in
 AD subjects should COR388 HCl be 
effective. A
vailable data indicate that Alzheimerâ€™s Disease Assessment Scale-
Cognitive Subscale 11 (ADAS-Cog 11) score increases by 2-4 points per year on 
average in subjects with mild to moderat
e AD (Ito 2013, Wattmo 2016). Therefore, a 
treatment period of [ADDRESS_32717] 2.5 points difference between active
 treatment and placebo on ADAS-Cog 11 
at the end of treatment peri od. The doses of 40 and 80 mg were selected to provide 
plasma lev
els of COR388 above the levels found to be therapeutic  in animal models, 
while maintaining safe exposure levels
 based on preclinical and clinical data 
available to date. The objecti ve of the open label extens ion portion of the study is to 
evaluate the safety and efficacy of COR388 HCl treatment in all subjects who want 
to participate and meet eligib
ility criteria.  
The frequency of visits is selected to prov ide close monitoring of subjectsâ€™ safety, 
without putting undue burden on the subjects
 and their caregivers. Similarly, study 
assessments are selected to provi de 
the essential data needed to assess the 
Protocol COR388-010  Version 7.0 Page 30 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 efficacy and safety of COR388 HCl, without burdening study subjects with 
unnecessary procedures or lengthy site visits. 
4.1.2 Efficacy Evaluations 
Primary Endpoint 
The two co-primary endpoints are: 
ï‚· Mean change in Alzheimerâ€™s Disease Assessment Scale-Cognitive Subscale 11 
(ADAS-Cog 11) from baseline to the end of treatment period; and 
ï‚· Mean change in Alzheimerâ€™s Disease Cooperative Study Group-Activities of Daily 
Living (ADCS-ADL) from baseline to the end of treatment period. 
 
Secondary Endpoints 
Secondary endpoints in all subjects include: 
ï‚· Change in Clinical Dementia Rating-Sum of Boxes (CDR-SB); 
ï‚· Change in Mini-Mental State Examination (MMSE); and 
ï‚· Change in Neuropsychiatric Inventory (NPI).  
 
Exploratory Endpoints 
Exploratory endpoints in all participat ing subjects include change from 
screening/baseline and/or Visi t 2 to the end of treatment period in the following 
measures: 
ï‚· Blood-based biomarkers in seru m and peripheral blood mononuclear cells 
(PBMCs); and 
ï‚· Saliva biomarkers of P. gingivalis  infection and inflammation. 
ï‚· Cerebrospi[INVESTIGATOR_872]: 
o CSF A È•42, total Tau, and phosphorylated Tau; 
o Bacterial DNA in the CSF on quantitat ive polymerase chain reaction (qPCR); 
and 
o CSF biomarkers. 
Exploratory endpoints in subjects participating in sub-studies include change from 
screening/baseline to the end of treatment period in the following measures: 
ï‚· Winterlight Speech Assessment (only in  English speaking subjects (primary 
language and only in the US and [LOCATION_006]); 
ï‚· Magnetic resonance imaging sub-study  (subjects who have MRIs done in 
conjunction with the study): 
o Hippocampal volume; and 
o Cortical thickness. 
Protocol COR388-010  Version 7.0 Page 31 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 ï‚· Clinical periodontitis s ub-study (subjects enrolle d at selected sites):  
o Pocket Depth (PD); 
o Clinical Attachment Level (CAL) at 6 sites per tooth (distobuccal [DB], buccal 
[B], mesiobuccal [MB], distolingual [DL ], lingual [L], and mesiolingual [ML]); 
o The percentage of sites with Bleeding on Probing (BOP); and 
o Biomarkers of P. gingivalis infection and inflammation in subgingival plaque 
(SGP) and buccal cell swabs. 
Safety Endpoints 
Safety endpoints include: 
ï‚· The incidence and severity of TEAEs;  
ï‚· Vital signs and physical examinations;  
ï‚· Laboratory values;  
ï‚· MRI scans; 
ï‚· 12-lead ECGs; and  
ï‚· C-SSRS.  
 
4.1.3 End of Study Definition 
End of study is Safety Follow-up Visit 11 or Visit OLE-9 (if subject participates in the 
open label extension portion of the study), unless the Investigator determines that 
treatment of a given subject should be stopped or  interrupted for safe ty or tolerability 
reasons, the subject withdraws consent, or the Sponsor decides to stop the study.  
[ADDRESS_32718] will receive study treatment according to the randomization scheme. 
The study drug will be provided in capsule form for oral administration. Subjects will 
be instructed to take the capsules with water twice a day, one capsule after waking 
in the morning and one before bed, ideally  12 hours apart and no less than 6 hours 
apart. 
5.2  Randomization to Treatment Groups Subjects who meet all eligibility criter ia will enter the treatm ent period and will be 
randomized 1:1:1 to receive 40 mg COR388 HCl, 80 mg COR388 HCl, or placebo 
twice a day. Randomization will be stratified by [CONTACT_33313] (MMSE Â•12 and 
Â”18, and MMSE Â•19 and Â”24) and Apolipoprotein E (ApoE4 positive either 
homozygous or heterozygous vs. all others) genotype to assure balanced distribution of mild and moder ate AD and a balanced distri bution of ApoE4 subjects, 
across treatment arms.  All participants will be centrally assigned to randomized 
Protocol COR388-010  Version 7.0 Page 32 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 study intervention using an Interactive Resp onse System (IRS). All subjects in the 
open label extension portion of the study will receive 40 mg or 80 mg COR388 HCl. 
5.3 Packaging and Labeling 
Study drug will be packaged in blister packs and assembled into weekly cards each 
containing 16 capsules: 2 capsules fo r each day of the week and 2 additional 
capsules to be used only if instructed by [CONTACT_737] (late visits, damaged or lost 
capsules, etc.). The capsules will be i dentical in appearance, but their contents will 
depend on the subjectâ€™s treatment assignmen t. The cards containing the blister 
packed capsules will be labeled in comp liance with country- specific labeling 
requirements.  
5.4 Study Drug Supply, Storage, and Handling 5.4.1 COR388 HCl 
The COR388 HCl capsules are orange, opaque, size 3 hydroxypropyl 
methylcellulose (HPMC) capsules contai ning the appropriate dose of COR388 HCl 
based on the treatment arm.  The capsules should be stored at room temperature.  
The study drug will be kept in a secure location that is accessible only to study 
personnel whom the Investigator has aut horized to dispense/prepare study drug.
 
5.4.[ADDRESS_32719] be stored at room temperature.  
The placebo capsules will be kept in a secu re location that is accessible only to 
study personnel whom the Investigator has  authorized to dispense/prepare study 
drug.  
5.4.3 Unblinding of Indi vidual Study Subjects  
From Screening (Visit 1) through the Sa fety Follow-up Visit (Visit 11), the 
Investigator should not become unblinded unless knowledge of the treatment is 
required for the subjectâ€™s safety and medical care. 
In the event of an SAE requiring identification of the study drug administered to an 
individual subject, the Investigator will access the IRS using the emergency unblinding instructions. The IRS will record the name [CONTACT_33357], the date and time of  the request, and the subject number and age. The 
Sponsor will be informed within [ADDRESS_32720] supervision of the 
Investigator. Investigators should maintain  records that document adequately that 
the subjects were provided the doses specified by [CONTACT_33314]. At the end of the 
study, or as directed, all study drugs, in cluding unused, partially used, and empty 
containers, will be returned to the S ponsor/designee or will be destroyed. 
5.[ADDRESS_32721] be returned at each  visit, as compliance will 
be assessed by [CONTACT_33315]. Noncompliance is defined as taking less than 80% 
or more than 120% of investigational product during any out patient evaluation period 
(visit to visit). Discontinuation for noncompl iance is at the Investigatorâ€™s discretion 
and is to be noted on the electronic Case Report Form (eCRF). 
[ADDRESS_32722] questions about 
eligibility of specific subjects. 6.1 Inclusion Criteria 
Subjects will be eligible to participate in this  study if they meet all of the following 
criteria:  
1. Subject has provided full written info rmed consent prior to the performance of 
any protocol-specified procedure; or if unable to provide informed consent 
due to cognitive status, subject has prov ided assent and a legally authorized 
representative has provided full wri tten informed consent on behalf of the 
subject. 
2. Caregiver has provided full written informed consent, on a separate informed 
consent form (ICF), on his/her own behalf prior to the performance of any 
protocol-specified procedure.  
Protocol COR388-010  Version 7.0 Page 34 
17 May 2021 
Cortexyme, Inc.  Confidential Information Male and female subjects must be 55 years to 80 years of age, at the time of
consent.
Subject has probable AD dementia according to the NIA-AA criteria
(McKhann 2011) with clinical evidence of progressive cognitive decline in the
last year. Clinical decline will be determined based on serial cognitive test
scores, if available, or subject/car
egiver report as documented by [CONTACT_33316].
Subject has an MMSE score between 12 and 24 inclusive at both screening
and 
Visit 2 and a Â”3-point difference between these visits.
Subject has a Modified Hachinski score Â” 4 at screening.
Subject has brain MRI scan consistent with the diagnosis of AD performed
during the screening period. Computed Tomography scan can be used only if
the subject has an absolute contraindication for MRI.
Subject has a primary caregiver willing to accept responsibility for supervising
the treatment (e.g., administering
 study drug), accompanying the study
subject to clinic visits and assessing the condition of the subject throughout
the study in accordance with all protocol requirements.
Subject is not likely to experience a change in living conditions (e.g.,
institutionaliz
ation, moving to a differ ent city, etc.), or change in primary
caregiver, during 
participation in the trial.
 Subjects with background symptomatic therapy with acetylcholinesterase
inhibitors, 
and/or memantine, are allowed as long as the dose has been
stable for 90 days prior to screening and no changes are planned during the
study.
 
Subjects who have occasional use of sedative agents are acceptable, but
these agents should not be given wit
hin 48 hours prior to cognitive
assessments.
 
Subjects who have background medications used for stable chronic illnesses
that are not prohibited by
 [CONTACT_33317]. The dose of psychoactive
drugs must be stable for [ADDRESS_32723] be
planned during the study unless for safety reasons.
 
Subject has body mass index <38 kg/m2 at Screening.
 
Subject must be able to ingest oral medications and can swallow the study
drug without breaking or crushing.
 Subject must be willing to undergo Apolipoprotein E genotype (ApoE) genetic
testing (ApoE results may be disclosed after trial completion).
 
Subjects participating in the study must meet one of the following criteria:
DFemales: Surgically sterilized (e.g., hysterectomy, bilateral
oophor
ectomy or tubal ligation) for at least 6 months or
postmenopausal (postmenopausal females must have no menstrual
bleedi
ng for at least 1 year). If not postmenopausal, agree to use a
highly effective method of contraception that can achieve a failure rate
Protocol COR388-010  Version 7.0 Page 35 
17 May 2021 
Cortexyme, Inc.  Confidential Information of less than 1% per year when used c onsistently and correctly, such as 
hormonal contraception or a double ba rrier method (e.g., intrauterine 
device plus condom or true abstinence defined as in line with the 
preferred and usual lifestyle of th e subject. Periodic abstinence e.g. 
calendar, ovulation, symptothermal, post-ovul ation methods are not 
acceptable. Declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods  of contraception) from [ADDRESS_32724] negative human 
chorionic gonadotropin ( È•-hCG) test for pregnancy at screening.  
b. Males who have not had a va sectomy must use appropriate
contraception methods (barrier or true abstinence defined as in line
with the preferred and usual lifes tyle of the subject. Periodic
abstinence e.g. calendar, ovulation,  symptothermal, post-ovulation
methods are not acceptable. Declarat ion of abstinence for the duration
of a trial, and withdrawal are not a cceptable methods of contraception)
from [ADDRESS_32725] dose.
Open Label Extension:  Subjects will be eligible to participate in the open label 
extension portion of the study if they meet inclusion criteria # 8, 9, 10, 11, 12, 14, 
and 16 above. Subjects with any change in their medical history that in the 
Investigatorâ€™s opi[INVESTIGATOR_33280]â€™s risk of participat ing in the study or 
confounding study assessment should not continue in the open label extension 
portion of the study. The Investigator shoul d contact [CONTACT_33318]. NOTE: Effective 16 February 2021, the OLE portion of the 
study was terminated by [CONTACT_1034]. 
6.2 Exclusion Criteria 
Subjects will not be eligible to participate in  this study if they  meet any of the 
following exclusion criteria:  
1. Subject has imaging consistent with other differential de mentia diagnoses
other than the diagnosis of AD. For example, any suggestion of vascular
disease including multiple infarction invo lving large blood vessels or localized
single infarction (angular gyrus, thal amus, anterior cerebral artery and
posterior cerebral artery region), multip le lacunae of the basal nuclei or white
matter or extensive lesions of the periv entricular white matter or combination
of several lesions are considered excl usionary. Additionally, any single lacune
in an area known to impact cognition such as the hippocampus will also be
exclusionary. Finally, Probable CAA with/without supporting pathological
evidence according to the modified [LOCATION_011] criteria, if in the opi[INVESTIGATOR_33281], would be exclusionary.Importantly, should there be any ev idence of neurologi c
  symptoms between
scanning and baseline visits, rescanning  is necessary to ensure proper
patient selection.
Protocol COR388-[ADDRESS_32726] has had an increase or restoration of cognition based on medical
history.
3. Subjects who meet the following im aging exclusion criteria will not be
included in this study:
a. Claustrophobia that will result in significant anxiety and difficulty lying
still for brain imaging (MRI or CT scan).
b. Severe motor problems or chroni c pain indication that prevents the
subject from lying still for brain imaging.
4. Subject with history of cancer requiri ng systemic therapy in the last 5 years;
except for localized cancer of the skin and in-situ cervical cancer successfully
treated with surgical excision.  Stable (for at least 90 days) prostate cancer is
allowed.
5. Subject has a contraindication for LP , such as infected skin over the needle
entry site, possible increased intracranial  pressure, severe thrombocytopenia
or coagulopathy, suspected spi[INVESTIGATOR_33282], or spi[INVESTIGATOR_33283].
6. Subject has evidence of clinically  significant unstable cardiovascular,
pulmonary, renal, hepatic, gastrointestinal , neurologic or metabolic disease
within [ADDRESS_32727] has any of the follo wing cardiovascular conditions:
a. Unstable angina, uncompensated and/or symptomatic  congestive heart
failure (Grade 2 or higher on the [LOCATION_001] Heart Association scale) or,
myocardial infarction within 6 months.
b. Acute or poorly controlled blood pressure >180 mmHg systolic or
>100 mmHg diastolic.
c.Current, or recent history of, any of  the following that  are clinically
significant in the investigator's judgment:  arrhythmia, hypotension,
heart block (1st, 2nd or 3rd degree AV block), ANY bundle branch
block, ventricular pacing,  symptomatic ectopy, unstable arrhythmias
including atrial fibrillation; stabl e atrial fibrillation is allowed.
d. History of prolonged QT or prolonged QT on screening ECG
(QTcF ï‚³480 msec).
e. History of prolonged PR interval or prolonged PR interval on screening
ECG (PR >210 msec).
f. History of prolonged QRS interval or prolonged QRS interval on
screening ECG (QRS >120 msec).
g. Supraventricular or ventricu lar ectopy on the screening ECG or
Brugada pattern on the ECG.
Protocol COR388-[ADDRESS_32728] with major stroke, uncontroll ed seizure disorder, or other medical
illnesses that in the Investigatorâ€™s opi[INVESTIGATOR_33269]â€™s risk of
participation in the study or confound study assessments.
9. Subject with history or current evi dence of major neurological or psychiatric
illness such as schizophrenia, bipolar disorder, Parkinsonâ€™s Disease, etc.Subjects with major depressive disorder that may interfer e with the patientâ€™s
ability to perform the study and all a ssessments. NOTE: Mild depression or
depressive mood arising in t he context of AD are not criteria for exclusion.
The use of anti-depressants or the use of anti-epi[INVESTIGATOR_33284]-seizure-related treatment is allowed if the dose has remained stable for at
least [ADDRESS_32729] with history of violent or aggressive behavior that requires medication
to control.
11. Subjects with active suicidal thoughts (Type 4 or 5 on the C-SSRS) in the
6 months preceding screening or at baseli ne; or have a history of a suicide
attempt in the previous 2 years, or more than 1 lifetime suic ide attempt; or are
at serious suicide risk in the Inve stigatorâ€™s clinical judgment.
12. Subject with history of alcohol or drug use disorder wit hin [ADDRESS_32730] has participated in another In vestigational New Drug (IND) research
study involving small molecule drugs wit hin [ADDRESS_32731] has any of the followi ng laboratory findings at screening:
a. Alanine aminotransferase >3 x u pper limit of normal (ULN), aspartate
aminotransferase >[ADDRESS_32732], or history of clinically significant liverdisease in the Investigatorâ€™s judgment.NOTE : Subjects with ALT or AST >[ADDRESS_32733] at Visit 9/Week 40 will not
be eligible to participate in OLE.NOTE: Effective 16 February 2021, the OLE portion of the study wasterminated by [CONTACT_1034].
b. Hemoglobin Â”10 g/dl.
c. International Normalized Ratio (INR) >1.5 or total bilirubin >1.[ADDRESS_32734]
(unless subject has evidence of Gilbertâ€™s disease).
d. Creatinine clearance (CL) of <45 ml/min.
e. Poorly controlled diabet es as defined by [CONTACT_33308] A
1C (HbA 1C) >8.
Protocol COR388-010  Version 7.0 Page 38 
17 May 2021 
Cortexyme, Inc.  Confidential Information f. Positive blood screen for Human Immunodeficiency Virus (HIV 1 and
2), Hepatitis B surface antigen (HBsAg ), or Hepatitis C virus antibodies
(HCV-Ab) at Screening.
g. Positive urine screen for drugs of abuse that include opi[INVESTIGATOR_858], cocaine,
amphetamines, or barbiturates.
17.Subject has abnormal laborator y tests that suggest an alternate etiology for
dementia, such as serum vitamin B12 def iciency, thyroid function abnormality,
severe anemia, electrolyte abnormality, or  positive syphilis serology. In these
cases, the patient should be re-evaluated to determine if these potential
causes of dementia have been address ed. Only if these causes have been
ruled out as the cause of the dem entia can the patient be enrolled.
18. Use of systemic (i.e., oral, intravenous, etc., but not topi[INVESTIGATOR_2855]) antibiotics in the
last 60 days or history of recurrent infe ction that requires chronic or repeated
courses of antibiotics.
Open Label Extension:  Subjects will not be elig
ible to participate in open label 
extension portion of the study if they meet any of the following exclus ion criteria # 1, 
4, 6, 7, 8-12, 15, 16 a, b, c, d and e. Laboratory testing and ECG results from Visit 9 
will be used to evaluate eligibility. Subjec ts with any change in their medical history 
that in the Investigatorâ€™s opi[INVESTIGATOR_33285] e the subjectâ€™s risk of participating in the 
study or confounding study assessment should not continue in the open label 
extension portion of the study. The Invest igator should contact [CONTACT_33319]. NOTE: Effective [ADDRESS_32735] Restrictions 
6.3.1 Prior and Concomitant Medications 
Subjects will not be allowed to use medications or combinations containing 
medications from prohibited classes during participation in the study (i.e., from 
Screening (Visit 1) through Safety Follow- up Visit 11 or Visit OLE-9 for subjects 
participating in OLE. Prohibited conc omitant medication classes include: 
anticholinergics, CNS-penetrant antih istamines, and antipsychotics.  
The use of prescribed benzodiazepi[INVESTIGATOR_33286]/hypnotics are allowed during the study but should not be used 48 hours before any study visit with cognitive 
testing.  
The use of prescribed acetyl cholinesterase inhibitors (e.g., donepezil, rivastigmine, 
etc.) or memantine is allo wed during the study as long as the dose has been stable 
for at least [ADDRESS_32736] arting new medication 
during participation in the study should be avoided, unless deemed necessary by [CONTACT_3786]. 
Systemic (i.e., oral, intravenous, etc., but not  topi[INVESTIGATOR_2855]) antibiotics are prohibited in the 
last 60 days prior to Screening (Visit 1), or hi story of recurrent infection that requires 
chronic or repeated courses of antibiotics . 
Patients requiring treatment with prophylactic antibiotics in order to undergo 
minimally invasive oral examination procedures (measurement s of pocket depth, 
gingival margin and bleeding on probing) du e to preexisting medical conditions such 
as artificial heart valve, hi story of rheumatic fever or recent (within a year) joint 
replacement surgery, or currently receiv ing immunosuppressive t herapy are eligible 
to participate in the study; however, they  should be excluded from  participating in 
oral examinations.  
The use of any over-the-counter medici nal products, including herbal and dietary 
supplements, are allowed unless, in the opi[INVESTIGATOR_689], the 
administration 
of the over-the-counter medicinal product could affect the subjectâ€™s 
safety or the results of the study. 
All medications (including drug name, dos e, and dose regimen)  administered from 
30 days prior to Visit 1 through the Safety Fo llow-up Visit (Visit 11) will be recorded 
in the source documents and on the Prior
 and Concomitant Medication electronic 
Case Report Form (eCRF). 
[ADDRESS_32737] of 3 periods: Screeni ng period up to 6 wee ks, treatment period 
up to 48 weeks, and a safety follow-up period of 6 weeks.  When feasible, study visits 
should be performed at the same time  of day for the same subjec t. 
7.1 Screening: Visit 1 (Day -42 to Day -1) 
During the screening period, the eligibility of subjects will be confirmed according to 
the Schedule 
of Evaluations in this protocol (see Table 1). The following evaluations 
will be performed at Screening in the follo wing order as close as possible when 
feasible: 
1. Obtain informed consent from subj ect, and caregiver informed consent signed
by [CONTACT_33320];
2. Past medical history and confirmati on of cognitive decline in the last
12 months;
3. Concomitant medications;
4. Inclusion/exclusion cr iteria for eligibility;
5. Modified Hachinski;
6. Columbia-Suicide Severi ty Rating Scale (C-SSRS);
Protocol COR388-010  Version 7.0 Page 40 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 7. Mini-Mental State Examination (MMSE). Subjects with MMSE score of 12-24, 
inclusive, will have the rest of t heir screening procedures performed or 
scheduled); 
8. Alzheimerâ€™s Disease Assessment  Scale-Cognitive Subscale 11 
(ADAS-Cog 11); 
9. Clinical Dementia Rating,  Sum of Boxes (CDR-SB); 
10. Winterlight Speech Assessment (only in English speaking (primary language 
subjects and only in the US and [LOCATION_006]); 
11. 12-lead electrocardiogram (ECG); 
12. Weight; 13. Vital signs; 
14. Full physical examination, includ ing height and body mass index (BMI) 
calculation; 
15. Urine drug screen; 16. Urine pregnancy test (women of  child bearing potential only); 
17. Blood/urine sample collection for: 
a. Serology (Hepatitis C virus anti bodies [HCV-Ab], Hepatitis B surface 
antigen [HBsAg], Human Immunodeficiency Virus [HIV] 1 and 2); 
b. Apolipoprotein E (Apo E) genotypi[INVESTIGATOR_007];  
c. Follicle stimulating hormone (FSH) for peri-menopausal (irregular 
menstrual periods) or post-menopaus al (no menstrual period for 
>12 months) female subjects;  
d. Vitamin B12 
e. Thyroid function tests 
f. Syphilis g. Pregnancy test (only if urine pregnancy test is positive); and 
h. Safety laboratory tests; 
18. Saliva collection; 19. Oral examination and co llection of oral biomarker samples (subgingival 
plaque [SGP] and buccal cell swabs) (only at selected sites); and 
20. Magnetic resonance imaging (MRI) of t he brain. Computed Tomography (CT) 
scans of the brain can used instead of MRIs only in subjects who have an 
absolute contraindication for MRI. 
Screening procedures can be done on multiple days if needed, with more invasive 
procedures done after other screening procedures are comp leted. A screen failure is 
any subject who signs the informed consent  but does not qualify for the study or 
discontinues the study  prior to randomization. A subject can be rescreened if the 
Principal Investigator [INVESTIGATOR_33287] t may qualify for the study upon rescreening, 
and if the Medical Monitor agrees. 
7.2 Study Treatment: Visit 2 (Day 0) 
Subjects who meet all of the eligibility criteria wil l be scheduled for Visit 2.  
Note: To accommodate the logistics of performing the baseli ne LP procedure, a 
separate visit within 7 days prior to V2 /Day [ADDRESS_32738] dose of study 
drug will be administered. 
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. MMSE;  
2. Lumbar puncture to collect cerebrospi [INVESTIGATOR_872] (CSF) may be conducted up to 
7 days prior to other procedures listed below; 
3.  Inclusion/exclusion criteria to  assess for continued eligibility.  
4. ADAS-Cog 11;  
5. Alzheimer's Disease Cooperative Study Group - Activities of Daily Living 
(ADCS-ADL); 
6. CDR-SB; 7. Randomization; 
8. Concomitant medications; 9. Symptom-based physical examination;  
10. Vital signs; 
11. Neuropsychiatric Inventory (NPI); 12. C-SSRS; 
13. Urine drug screen; 
14. Blood/urine sample collection: 
a. Pharmacokinetics (PK): A pre-dose trough sample will be drawn 
immediately prior to the AM dose.  The exact times of AM dosing and 
PK sample collections at the site will be documented.  
b. Serum and whole blood (peripheral  blood mononuclear cells [PBMCs]) 
for biomarkers; and 
c. Safety laboratory tests; 
15. Saliva collection; 
16. Winterlight Speech Assessment (only in English speaking (primary language) 
subjects and only in the US and [LOCATION_006]); 
17. Adverse events;  18. Administer study drug at the site;  
19. 12-lead ECG 1-1.[ADDRESS_32739]-dose; 
20. Blood sample collection: Second PK blood draw [ADDRESS_32740]-
dose; and 
21. Dispense study drug. 
 
A screen failure is any subject who signs the informed consent but does not qualify for the study or discontinues the study prior to randomization. A subject can be 
rescreened if the Principal Investigator [INVESTIGATOR_33268], and if the Medical Monitor agrees. 
Protocol COR388-010  Version 7.0 Page 42 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 7.3 Study Treatment: Visit 3 (Day 14 Â± 2) 
Note: Please make every effort possible to have the visit scheduled in the morning 
so the AM dose can be taken in the mornin g. Ideally, daily doses should be taken 12 
hours apart and no less than 6 hours apart. The following evaluations will be performed at this visit: 
1. Concomitant medications; 
2. Symptom-based physical examination; 
3. Vital signs; 
4. C-SSRS; 5. Blood/urine sample collection: 
a. Safety laboratory tests; and b. PK
 - A pre-dose trough sample will be drawn. The exact times of AM 
dosing and PK sample collections at the site wil l be documented. 
6. 12-lead ECG before dosing drug (trough)  
7. Administer study  drug at the site; 
8. Adverse events;  
9. 12-lead ECG 1-1.[ADDRESS_32741]-dose; 
10. Blood sample collection: Second  PK blood draw 60 minutes Â± [ADDRESS_32742]-dose; and 
11. Dispense study drug. 
7.4 Study Treatment: Visit 4 (Day 42 Â± 3)  
The following evaluations will be performed at this visit: 
1. Concomitant medications; 
2. Symptom-based physical examination; 
3. Vital signs; 
4. C-SSRS; 5. Blood/urine sample collection: 
a. Safety laboratory tests; 
6. 12-lead ECG; 7. Adverse events; and  
8. Dispense study drug. 
7.5 Study Treatment: Visit 5 (Day 84 Â± 3)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. ADAS-Cog 11; 
2. MMSE; 3. ADCS-ADL; 
4. CDR-SB; 
5. Concomitant medications; 
Protocol COR388-010  Version 7.0 Page 43 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 6. Symptom-based physical examination; 
7. Vital signs; 
8. C-SSRS; 
9. Winterlight Speech Assessment (only in English speaking (primary language 
subjects and only in the US and [LOCATION_006]); 
10. Blood/urine sample collection: 
a. Safety laboratory tests; 
11. 12-lead ECG; 
12. Adverse events; and 
13. Dispense study drug. 
7.6  Study Treatment: Visit 6 (Day 126 Â± 3)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. Concomitant medications;  
2. Symptom-based physical examination; 
3. Vital signs;  4. C-SSRS; 
5. Blood/urine sample collection: 
a. Safety laboratory tests; and 
6. Adverse events. 
7.7 Study Treatment: Visit 7 (Day 168 Â± 3)  
Note: Please make every effort possible to have the visit scheduled in the morning 
so the AM dose can be taken in the mornin g. Ideally, daily doses should be taken 12 
hours apart and no less than 6 hours apart. The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
 
1. ADAS-Cog 11; 
2. MMSE; 
3. ADCS-ADL; 4. CDR-SB; 
5. NPI; 
6. Winterlight Speech Assessment (only in English speaking (primary language 
subjects and only in the US and [LOCATION_006]); 
7. Concomitant medications; 8. Oral examination and collection of oral biomarker samples (SGP and buccal 
cell swabs) (only at selected sites); 
9. Saliva collection;  10. Symptom-based physical examination; 11. Vital signs; 
Protocol COR388-010  Version 7.0 Page 44 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 12. C-SSRS; 
13. Blood/urine sample collection: 
a. Safety laboratory tests; b. PK 
- A pre-dose trough sample will be dr awn and the subject will then 
take their dose of study drug on-si te. The exact times of AM dosing 
and PK sample collections at the site will be documented. 
c. Serum and whole blood (PBMCs) for biomarkers; 
14. Adverse events; 
15. 12-lead ECG before dosing drug (trough); 
16. Administer study drug  at the site;  
17. 12-lead ECG 1-1.[ADDRESS_32743]-dose; 18. Blood sample collection: Second PK blood draw 2 hours Â± [ADDRESS_32744]-
dose; and 
19. Dispense study drug. 
7.8 Study Treatment: Visit 8 (Day 224 Â± 3)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible:  
1. Concomitant medications;  
2. Symptom-based physical examination; 3. Vital signs;  
4. C-SSRS; 
5. Blood/urine sample collection: 
a. Safety laboratory tests; and 
6. Adverse events. 
7.9 Study Treatment: Visit 9 (Day 280 Â± 8)  
Note: Please make every effort possible to have the visit scheduled in the morning 
so the AM dose can be taken in the mornin g. Ideally, daily doses should be taken 12 
hours apart and no less than 6 hours apart. The following evaluations will be performed at this visit in the following order as 
close as possible when feasible: 
1. Administer study  drug at the site 
2. Blood/urine sample collection 
a. Safety laboratory tests; 
b. PK â€“ A single post-dose sample wil l be drawn from each subject while 
on-site at the clinic at  3 hours Â± [ADDRESS_32745] times 
of AM dosing and PK sample collecti on at the site will be documented. 
3. Adverse events; 
4. 12-lead ECG 1-1.[ADDRESS_32746]-dose;   
5. ADAS-Cog 11; 
6. MMSE; 
Protocol COR388-010  Version 7.0 Page 45 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 7. ADCS-ADL; 
8. CDR-SB; 
9. Concomitant medications; 
10. Symptom-based physical examination; 11. Vital signs; 
12. C-SSRS; and 
13. Dispense study drug. 
7.10 Study Treatment: Visit 10/Earl y Termination (Day 336 Â± 8)  
Note: To accommodate the logistics of perfo rming the LP procedure, it may be done 
up to 7 days prior to V10/Day 336. Please make every effort possible to have the 
visit scheduled in the morning so the AM do se can be taken in the morning. Ideally, 
daily doses should be taken 12 hours apart and no less than 6 hours apart. 
The following evaluations will be performed at this visit or at Early Termination in the 
following order as close as possible when feasible: 
 
1. Administer last dose of double-blind study drug  at the site;  
2. Blood/urine sample collection: 
a. Safety laboratory tests; 
b. PK 
- A single post-dose sample will be dr awn from each subject while 
on-site at the clinic at  4 hours Â± [ADDRESS_32747] times 
of AM dosing and PK sample coll ections at the site will be 
documented.  
c. Serum and whole blood (PBMCs) for biomarkers; d. Pregnancy test (only if uri ne pregnancy test is positive); 
3. Adverse events;  
4. Oral examination and co llection of oral biomarker samples (SGP and buccal 
cell swabs) at selected sites (will be completed within 8 days before Visit 10 
[or Early Termination] when applicable). 
5. 12-lead ECG 1-1.[ADDRESS_32748] an absolute contraindication 
for MRI; 
7. ADAS-Cog 11; 
8. MMSE; 
9. ADCS-ADL; 10. CDR-SB; 
11. NPI; 
12. Winterlight Speech Assessment (only in English speaking (primary language 
subjects and only in the US and [LOCATION_006]); 
13. Concomitant medications; 14. Symptom-based physical examination; 15. Saliva collection; 
Protocol COR388-010  Version 7.0 Page 46 
17 May 2021 
Cortexyme, Inc.  Confidential Information 16. Weight; 
17. Vital signs; 
18. Lumbar puncture to collect CSF;
19. Urine pregnancy test (women of  child bearing potential only);
20. C-SSRS; 
21. Informed consent will be obtained for s ubjects who agree to participate in the
open label extension port ion of the study; and
22. Inclusion/exclusion will be evaluated to determine eligibility for subjects who
want to participate in the open label  extension portion of the study.
Dispense OLE study drug â€“ s ubjects who participate in  OLE only. The subject
should be instructed to take the first dose of COR388 in the morning of thenext day.
NOTE: Effective 16 February 2021, the OLE portion of the study wasterminated by [CONTACT_1034].
7.11 Safety Follow-up Phone Calls: (Days 343 Â± 2 and 357 Â± 2) 
Adverse events and any changes to concomit ant medications will be evaluated during 
these phone calls. The follow-up phone calls wil l be structured and scripted to ensure 
completeness and standardization. The general structure of the i nquiry will be open 
ended inquiry about any new symptoms, specif ic questioning about any reported sign 
or symptom and then a struct ured questioning about neurolog ic and withdrawal sign 
and symptoms by [CONTACT_33321][INVESTIGATOR_33288].  These will be conducted after either Visit 10 or Early Termination.  
NOT
E: Subjects who choose to participate in the open label extension portion of the 
study will not complete the safety follow-up phone calls and continue with the 
Sched
ule of Evaluations in Table 2.   
NOTE: Effective 16 February 2021, the OLE porti on of  the study was terminated by 
[CONTACT_1034]. 
7.12 Safety Follow-up Visit: Visit 11 (Day 378 Â± 8) 
After
 completion of study treatment, subj ects  will continue to be monitored on the 
study for 6 weeks and will return for the Safety Follow-up Visit (Week 54). 
For
 subjects with early termination,  end of study procedures (Week 48)  will be 
performed,
 and subjects will be encouraged to re turn to the clinic for the Safety 
Follo
w-up Visit after 6 weeks. 
NOTE: Subjects who choose to participate in the open label extension portion of the 
study will not complete the safety follow-up visit and continue with the Schedule of 
Evaluations in Table 2. 
NOT
E: Effective 16 February 2021, the OLE porti on of  the study was terminated by 
[CONTACT_1034]. 
Protocol COR388-010  Version 7.0 Page 47 
17 May 2021 
Cortexyme, Inc.  Confidential Information The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. ADAS-Cog 11;
2. MMSE;
3. ADCS-ADL;
4. CDR-SB;5. Concomitant medications;
6. Saliva collection;
7. Symptom-based physical examination;8. Vital signs;
9. C-SSRS;
10. Blood/urine sample collection:
a. Safety laboratory tests
11. 12-lead ECG; and12. Adverse events. 
7.13 Increased Safety Laboratory Monitoring (Liver Safety Monitoring) 
Per DMC recommendation (following the No vember 16, 2020 meet ing) the following 
increased laboratory analyte te sting is being implemented: 
ï‚·Every 2 weeks for the initial 12 weeks
ï‚·Every 3 weeks as of Week 12 through Week 24
ï‚·Every 4 weeks as of Week 24 through Week 32
Liver Safety Monitoring (laboratory analyte testing) must be performed at each 
study 
visit within the prespecified visit window (see Table 1, Schedule of 
Evaluations) OR the study drug dosing must be interrupted until the testing is done.  
Protocol COR388-010  Version 7.0 Page 48 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 7.14 Open Label Extension (OLE) 
NOTE: Effective [ADDRESS_32749] udy. If subjects meet inclus ion and none of the exclusion 
criteria, and sign the informed consent, they  will continue in the open label extension 
portion and not complete the Safety Follo w-up Phone Calls or the Safety Follow-up 
Visit: Visit 11 (Day 378 Â± 8). Laboratory test ing and ECG results from Visit 9 will be 
used to evaluate eligibility. 
Subjects who are not eligib le or do not consent to the open label extension will 
proceed to the Safety Follow-up Phone Ca lls (Days 343 Â± 2 and 357 Â± 2) and the 
Safety Follow-up Visit: Visit 11 (Day 378 Â± 8). 
7.15 OLE Study Treatment: Visit OLE-1 (Day 350 Â± 3)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. Concomitant medications; 
2. Symptom-based physical examination; 3. Vital signs; 
4. C-SSRS; 
5. 12-lead ECG; 6. Blood/urine sample collection: 
a. Safety laboratory tests; 
7. Adverse events; and 8. Dispense study drug. 
7.16 OLE Study Treatment: Visit OLE-2 (Day 378 Â± 3)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. Concomitant medications; 
2. Symptom-based physical examination; 3. Vital signs; 
4. C-SSRS; 
5. 12-lead ECG;  6. Blood sample collection:  
a. Safety laboratory tests; 
7. Adverse events; and 8. Dispense study drug. 
Protocol COR388-010  Version 7.0 Page 49 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 7.17 OLE Study Treatment: Visit OLE-3 (Day 420 Â± 3)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. ADAS-Cog 11; 
2. ADCS-ADL; 
3. CDR-SB; 
4. Concomitant medications; 5. Symptom-based physical examination; 
6. Vital signs; 
7. C-SSRS; 8. Blood/urine sample collection: 
a. Safety laboratory tests; 
9. Adverse events; and 10. Dispense study drug. 
7.18 OLE Study Treatment: Visit OLE-4 (Day 504 Â± 3)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. ADAS-Cog 11;  
2. ADCS-ADL; 3. CDR-SB; 
4. Concomitant medications; 
5. Saliva collection; 6. Symptom-based physical examination; 
7. Vital signs; 
8. C-SSRS; 9. 12-lead ECG;  
10. Blood sample collection:  
a. Safety laboratory tests; 
11. Adverse events; and 12. Dispense study drug. 
7.19 OLE Study Treatment: Visit OLE-5 (Day 588 Â± 6)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. Concomitant medications; 
2. Symptom-based physical examination; 3. Vital signs; 
4. C-SSRS; 
5. Blood/urine sample collection: 
a. Safety laboratory tests; 
Protocol COR388-010  Version 7.0 Page 50 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 6. Adverse events; and 
7. Dispense study drug. 
7.20 OLE Study Treatment: Visit OLE- 6/Early Termination (Day 672 Â± 8)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. ADAS-Cog 11; 2. ADCS-ADL; 3. CDR-SB; 
4. Concomitant medications; 
5. Saliva collection; 6. Symptom-based physical examination; 
7. Weight 
8. Vital signs; 9. C-SSRS; 
10. 12-lead ECG;  
11. Urine pregnancy test (women of  child bearing potential only); 
12. Blood sample collection:  
a. Safety laboratory tests; b. Pregnancy test (only if urine pregnancy test is positive);  
13. Adverse events. 
14. Oral examination and co llection of oral biomarker samples (SGP and buccal 
cell swabs) at selected sites (will be completed within 8 days before Visit 
OLE-6 [or Early Termination] when applicable). 
7.21 OLE Safety Follow-up Phone Calls: Vi sits OLE-7 and OLE-8 (Days 679 Â± 2 
and 686 Â± 2) 
Adverse events, the C-SSRS, and any c hanges to concomitant medications will be 
reviewed and evaluated during these phone calls. The follow-up phone calls will be 
structured and scripted to ensure comp leteness and standardization. The general 
structure of the inquiry will be open ended in quiry about any new symptoms, specific 
questioning about any reported sign or sympt om and then a structured questioning 
about neurologic and withdrawal sign and sy mptoms by [CONTACT_33322][INVESTIGATOR_33289]. Thes e will be conducted after 
either Visit OLE-6 or Early Termination.   
OLE Safety Follow-up Visit: Visit OLE-9 (Day 714 Â± 8)  
The following evaluations will be performed at this visit in  the following order or as 
close as possible when feasible: 
1. ADAS-Cog 11; 
2. ADCS-ADL; 
3. CDR-SB; 4. Concomitant medications; 
Protocol COR388-010  Version 7.0 Page 51 
17 May 2021 
Cortexyme, Inc.  Confidential Information 5. Saliva collection;
6. Symptom-based physical examination;
7. Vital signs;
8. C-SSRS;9. 12-lead ECG;
10. Blood sample collection:
a. Safety laboratory tests;
11. Adverse events. 
Increased Safety Laboratory Monitori ng (Liver Safety Monitoring) 
Per DMC recommendation (following the No vember 16, 2020 meet ing), the following 
increased laboratory analyte te sting is being implemented: 
ï‚·Every 2 weeks for the initial 12 weeks
ï‚·Every 3 weeks as of Week 60 through Week 72
ï‚·Every 6 weeks as of Week 72 through Week 84
Liver Safety Monitoring (laboratory analyte testing) must be performed at 
each 
study visit within the prespecified visit window (see Table 2, Schedule of 
Evaluations) OR the study drug dosing mu st be interrupted until the testing is 
done.  
7.22 Unscheduled Visit(s) 
Subjects may return for an unscheduled visit at any time and evaluations will be 
performed, as necessary in the j udgment of the Investigator.    
7.23 Allowances in the Circumstance of a Public Health Emergency 
If an investigative site or the patients a ssociated with that site experience a public 
health emergency, such as a pandemic, t hen throughout that time, the following 
changes to what is written elsewhere in this  protocol are permissible at the discretion 
of the PI: 
â€¢ At-home and/or virtual visits:  Even when an investigative site
remains open to clinical trial patients coming on site, social distancing
strategies may result in some patients being unwilling or unable to
attend protocol-specific clinic visits .  For such reasons, scheduled clinic
visits may be replaced by [INVESTIGATOR_136]-home or virtual visits. This may include
visits by [CONTACT_33323] (or home healthcare providers, if applicable)
or virtual visits by [CONTACT_33324].
â€¢ Safety assessments:  Every effort should be made to continue
performing safety assessments on schedule.  This may require visits by
[CONTACT_33323] (or home healthcare providers, if applicable).
Protocol COR388-010  Version 7.0 Page 52 
17 May 2021 
Cortexyme, Inc.  Confidential Information â€¢ Transport of investigational product to support study drug 
administration:
 It is permissible for study drug to be shipped directly to 
the patient and/or caregiverâ€™s hom
e.  It is also permissible for patients 
or caregivers to ship used study drug back to the site.
â€¢ Visit windows: For safety assessments, the visit windows will remain
as given in 
Table 1 and Table 2, Schedule of Evaluations.
â€¢ Testing at local laboratories: If it is not practical to conduct testing on
site using kits from the central laboratory, then it is permissible to use a
local laboratory instead.
All instances when the above listed allowanc es are applied to the study conduct and 
its participants will be document ed within the study source documents and reflected 
within the visit specific case report forms  and protocol deviat ions log.     
[ADDRESS_32750], a written ICF will be obtained before any protocol-related 
activities at Screening (Visit 1).  An addi tional informed consent will be obtained at 
Visit 10 for subjects who qualify and want to participate in the open label extension 
portion of the study ( NOTE:  effective 16 February 2021, t he OLE portion of the study 
was terminated by [CONTACT_1034]). As part of this procedure, the Investigator or a 
designated representative must explain orally  and in writing the nature, duration, and 
purpose of the study, and the action of the investigational product in such a manner that the subject and (if applicable) subjectâ€™ s legal representativ e are aware of the 
potential risks, inconveniences, or adverse ef fects that may occur.  Subjects, or the 
subjectâ€™s legally authorized representative, must be given ample time to decide 
about the study participati on and opportunity to inquire  about details of the 
study.  Subjects should be informed that th ey may withdraw from the study at any 
time.  They will receive all information that is required by [CONTACT_33325] (ICH) guidelines. The Principal 
Investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a designated representative will provide the Sponsor or its 
representative with a copy of the Inst itutional Review Bo ard (IRB)/Independent 
Ethics Committee (IEC)-approved ICF before the start of the study. 
The subject or subjectâ€™s legally authoriz ed representative must be given a copy of 
the signed ICF, and the original is to be ma intained in the designated location at the 
site. A separate consent may be considered for subjects from sites participating in 
the dental portion of the study.  
The subjectâ€™s caregiver must also indica te their understanding of the study and their 
role as a caregiver to the subject during the study.  The subjectâ€™s caregiver must 
provide written agreement to their role as caregiver. 
Protocol COR388-[ADDRESS_32751] provide an IRB/IEC-approved written 
informed consent, if mentally competent according to IRB/IEC and local guidelines 
for consenting vulnerable populations. If the subject is not able to provide written 
informed consent, written informed consent must be obtained from a legally 
authorized representative on
 the subjectâ€™s behalf, and written assent must be 
obtained from the subject.  
Due to the nature of AD, subjects must 
identify a primary caregiver prior to 
enrollment in the study who will assist the subject with study participation. The 
primary caregiver 
must meet specific criteria set by [CONTACT_33326] a caregiver informed consent. 
8.[ADDRESS_32752] at Screening (Visit 1). 
The medical history will assess the subject for any disqualifying medical conditions 
as specified in the inclusion and exclusion criteria. The medical history will include all 
currently relevant history. When possi
ble, only diagnoses and surgeries will be 
recorded. It is not necessary to collect history for remote, resolved conditions such 
as past pediatric 
illnesses or surgeries, which probably do not affect suitability of the 
subject, unless the examining physician deems these conditions relevant to the 
subjectâ€™s current health status. Medication history should include prescription and 
over the counter medications, herbs, vitamins, and minerals. 
Concomitant medications will be recorded at Screening and at all subsequent study 
visits. 
Open Label 
Extension: Concomitant medications will be recorded at all visits and 
phone calls.
 NOTE: Effective 16 February 2021, the OLE portion of the study was 
terminated by [CONTACT_1034]. 
8.3 Mini-Mental 
State Examination (MMSE) 
The Mini-Mental State Examination (MMSE) ( Folstein 1975) is a widely used and 
validated assessment to be used to evaluate inclusion eligibility as well as an 
exploratory measure. The MMSE will be administered by a trained rater to assess 
the level of cognitive impairment. MMSE will
 be assessed as early in the screening 
period as possible. Subjects with MMSE score of 12-24, inclusive, will have the rest 
of their screening procedures 
performed or scheduled. The MMSE will be 
administered at Screening (Visit 1), Visit 2, Visit 5, Visit 7, Visit 9, Visit 10 (or Early 
Termination), and Visit 11 (Safety Follow-up Visit). The MMSE score should be 
ï‚³12 and ï‚£24 at both Screening (V isit 1) and Visit 2, and a ï‚£3-point difference 
between these visits, for inclusion in the study. The MMSE takes approximately 20 
minutes to complete. 
8.4 Randomization 
Subjects who meet all eligibility criteria will enter the treatment period and will be 
randomized 1:1:1 to receive 40 mg COR388 HCl, 80 mg COR388 HCl, or placebo 
Protocol COR388-010  Version 7.0 Page 54 
17 May 2021 
Cortexyme, Inc.  Confidential Information twice a day at Visit 2. Randomization will be strati fied by  [CONTACT_33313] (MMSE 
Â•12 and Â” 18, and MMSE Â• 19 and Â” 24) and Apolipoprotein E (A poE4 positive either 
homozygous
 or heterozygous vs all others) genotype to assure balanced distribution 
of mild and moderate AD and a balanced di s tr ibution of ApoE4 subjects, across 
treatment arms.  All participants will be c entra lly assigned to randomized study 
intervention using an Interact ive Respons e System (IRS). 
8.5 Dispense Study Drug 
Study drug will be dispensed to eligible subjects  at Visit 2, Visit 3, Visit 4, Visit 5, 
Visit 7, and Visit 9. 
Open
 Label Extension: Study drug will be dispensed to eligible subjects at Visits 10, 
OLE-1, OLE-2, OLE-3, OLE-4 and OLE-5. A pproximately the same number of 
subjects will be assigned to 80 mg and 40 mg, per the Sponsorâ€™s instructions. 
NOT
E: Effective 16 February 2021, the OLE porti on of  the study was terminated by 
[CONTACT_1034]. 
8.6 Alzheimerâ€™s Disease Assessment Scale-Cognitive Subscale 11 
(ADAS-Cog 11) 
The Alzheimer's
 Disease Assessment Scal e-Cogn itive items (ADAS-Cog) is an 
11-item
 scale which has been widely used in AD therapeutic research to assess
memory, other cognitive functions and praxis (Mohs 1988). The ADAS-Cog 11 will be 
performed by [CONTACT_33327]
measure cognitive ability and to evaluate change from Baseline.  The ADAS-Cog 11
is to be administered at Screening  (Visit 1), Visi t 2, Visit 5, Visit 7, Visit 9, Visit 10 (or
Early
 Termination), and Visit 11 (Safety  Follow-up Vis it). The ADAS-Cog 11 takes
approximately  30 minutes to complete.
Open Label Extension: The ADAS-Cog 11 is to be administered at Visits OLE-3, 
OLE-4, OLE-6 (or Earl y Termination)  and OLE-9 (OLE Safety Follow-up Visit). 
NOTE : Effective 16 February 2021, the OLE porti on of  the study was terminated by 
[CONTACT_1034]. 
8.7 Clinical Dementia Rating-Sum of Boxes (CDR-SB) 
The Clinical Dementia Rating
 Scale (Hughes 1982) is a global rating of the function of 
AD subjects assessed in six categories: memory, orientation, judgement and problem 
solving
, community affairs, home and hobbies, and personal care. It is based on a 
semi-structured interview conducted with the subject and identified primary caregiver. 
The Clinical De
mentia Rating-Sum of Boxes (CDR-SB) tool will be administered by a 
certified clinician and will be used to assess disease progression with cognitive and 
f
unctional changes.  The CDR-SB will be administered at Screening (Vis it 1), Visit 2, 
Visit 5, Visit 7, Visit 9, Visit 10 (or Early Termination), and Visit 11 (Safety Follow-up 
Visit). The CDR-SB takes approximately 45 minutes to 1 hour to complete. 
Protocol COR388-010  Version 7.0 Page 55 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 Open Label Extension: The CDR- SB will be administered at Visits OLE-3, OLE-4, 
OLE-6 (or Early Termination) and OL E-9 (OLE Safety Follow-up Visit). NOTE: 
Effective 16 February 2021, the OLE portion of the study was terminated by [CONTACT_429]. 
8.8 Alzheimerâ€™s Disease Cooperative Study  Group-Activities of Daily Living 
(ADCS-ADL) 
The Alzheimerâ€™s Disease Cooperative Study Group-Activities of Daily Living 
(ADCS-ADL) will be performed to assess the subj ectâ€™s ability to perform activities of 
daily living and will be administered at Visit 2, Visit 5, Visit 7, Visit 9, Visit 10 (or Early 
Termination), and Visit 11 (Safety Follo w-up Visit). The ADCS-ADL takes 
approximately 20 to 25 minutes to complete. 
Open Label Extension: The ADCS -ADL will be administered at  Visits OLE-3, OLE-4, 
OLE-6 (or Early Termination) and OL E-9 (OLE Safety Follow-up Visit). NOTE: 
Effective 16 February 2021, the OLE portion of the study was terminated by [CONTACT_429]. 
8.9 Neuropsychiatric Inventory (NPI) 
The Neuropsychiatric Inventory (NPI) is a 12-item scale which assesses behavioral 
disturbances commonly occurring in dem entia subjects. Through a structured 
interview with the identified primary caregiver 12 behavioral domains are assessed. 
The NPI [INVESTIGATOR_33290] a trained clinic ian at Visit 2, Visi t 7, and Visit 10 (or 
Early Termination). The NPI [INVESTIGATOR_33291] 15 minutes to complete, depending on psychopathology. 
8.10 Winterlight Speech Assessment 
The Winterlight Speech Assessment is an analysis of spontaneous speech detecting 
cognitive impairment to be administered by a trained clinician at Screening (Visit 1), 
Visit 2, Visit 5, Visit 7, and Visit 10 (or Early Terminatio n).  The Winterlight Speech 
Assessment will be administered to Englis h speaking (primary language) subjects 
and only in the US and [LOCATION_006]. The assessment  takes approximately up to 10 minutes 
to complete. 
8.11 Saliva Collection 
Saliva will be collected at the investigative sites at Screening (Visit 1), Visit 2, Visit 7, 
Visit 10 (or Early Termination), and Visit 11 (Safety Follow-up Visit). Saliva will be 
collected using provided kits following the procedure descri bed in the Laboratory 
Manual.  
Saliva samples collected at sites, and ot her oral fluids (SGP and buccal swabs) 
collected by [CONTACT_33328], will be processed and shipped to the central laboratory 
according to the Laboratory Manual, for anal ysis of bacterial DNA and biomarkers. 
Protocol COR388-010  Version 7.0 Page 56 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 Open Label Extension: Saliva wi ll be collected at Visits OLE-4, OLE-6 (or Early 
Termination) and OLE-9 (OLE Safety Follow-Up Visit). NOTE: Effective [ADDRESS_32753], to assess for the pres ence of periodontitis during Screening 
(Visit 1). Subjects will have follow-up oral examinations at Visit 7, Visit 10 and Visit 
OLE-6 or Early Termination.  Visit 10/ET and Visit OLE6/ET oral exam inations may be completed up to 8 days 
prior to Visit 10 (or ET), when applicable. 8.12.1 Oral Examination Procedures 
[IP_ADDRESS] Oral Examination 
The screening examination incl udes tooth count, identific ation of any hard or soft 
tissue lesions, assessment for presence of severe dental disease, determination of 
Pocket Depth (PD) and Clinical Attachment  Level (CAL) at 6 sites per tooth 
(distobuccal [DB], buccal [B], mesiobucca l [MB], distolingual [DL], lingual [L], 
mesiolingual [ML]), and assessment of Bleeding on Probing (BOP). All examination 
findings will be entered into the scoring tool, which will assist in the determination of 
the presence or absence of periodontitis . Please note that subjects who are 
otherwise eligible for this GAIN trial, but do not have at least 8 teeth, can still enroll 
in the study, but they are exem pt from the oral examination component of the study.   
[IP_ADDRESS] Measurement of Pocket Depths 
Pocket depths will be measured for each tooth present with a perio dontal probe with 
1 mm gradations on 6 tooth surface sites (MB, B, DB, ML, L, DL) and will be 
rounded down to the nearest millimeter. 
[IP_ADDRESS] Assessment of  Bleeding on Probing 
Bleeding on Probing on all 6 sites of each tooth will be recorded as present (â€œ1â€) or absent (â€œ0â€) immediately following the PD measures for each of the 4 probed sections of the dentition. 
[IP_ADDRESS] Measurement of Gin gival Margin Position 
The distance of the gingival margin (GM)  to the cementoenamel junction (CEJ) on 
each of the [ADDRESS_32754] millimeter.   
Clinical attachment levels will be calculated as a derived variable at the time of 
statistical analysis from the recorded m easures of PDs and GM to the CEJ. 
Protocol COR388-010  Version 7.0 Page 57 
17 May 2021 
Cortexyme, Inc.  Confidential Information [IP_ADDRESS] Determination of the Pr esence of Moderate to Severe 
Periodontitis 
Measurements of pocket depth (PD) and gingival margin (GM) and calculated 
attachment levels (AL) will be used to  determine the presenc e of periodontitis 
according to the Centers for Disease C ontrol/American Academy of Periodontology 
(CDC/AAP) criteria:  
No periodontitis  No evidence of mild, moderate or se vere periodontitis 
Mild periodontitis Â• 2 interproximal sites with AL Â•  3 mm, and Â• 2 interproximal 
sites with PD Â•  4 mm (not on same tooth)  
Or  
one site with PD Â• 5 mm 
Moderate Periodontitis Â• 2 interproximal sites with AL Â•  4 mm (not on same tooth),  
Or  Â• 2 interproximal sites with PD Â• 5 mm (not on same tooth) 
Severe Periodontitis  Â• 2 interproximal sites with AL Â•  6 mm (not on same tooth)  
And Â• 1 interproximal site with PD Â• 5 mm 
AL will be calculated as algebraic su m of PD - GM (PD minus GM). 
8.12.[ADDRESS_32755] or 
other appropriately trained site staff at Scr eening (Visit 1), Visit 7, Visit 10 and Visit 
OLE-6 or Early Termination (see Section 8.12 .1.5). Oral samples will be sent to the 
central laboratory to be distributed to a spec ialty laboratory for biomarker analysis.   
[IP_ADDRESS] Collection of Buccal Cells 
The subject will be instructed to refrain from  drinking or eating [ADDRESS_32756] at the dental office or main 
research clinic. 
[IP_ADDRESS] Collection of S ubgingival Plaque (SGP) 
The examiner will collect SGP samples us ing sterile endodontic paper point from 
teeth identified to have the maximum pocke t depth by [CONTACT_33329]. Multiple 
teeth can be used for sampling, and the sa me teeth used during the Screening visit 
will be used at the Follow-up visit in subj ects with evidence of periodontitis. The 
Protocol COR388-010  Version 7.0 Page 58 
17 May 2021 
Cortexyme, Inc.  Confidential Information details of sample collection and proce ssing procedures will be provided in the 
Laboratory Manual. 
8.13 Physical Examination 
A full physical examination will be performe d at Screening (Visit 1). A full physical 
examination includes assessment of t he following: head, neck and thyroid; eyes; 
ears; nose; throat; chest; lungs; heart; ce rvical lymph nodes; abdomen; skin; and the 
musculoskeletal and neurological systems.  A symptom-based physical examination 
will be performed at all clinic visits after the Screening visit. Symptom-based physical 
examination of other organs and systems (e.g., breast, rectal, and 
genitourinary/pelvic exams) will be conducted only when clinically indicated and 
consented to by [CONTACT_423]. It is not nec essary to collect information regarding 
well-healed surgical scars or tattoos. 
8.14 Brain Imaging Magnetic resonance imaging of the brain will be performed in all subjects at 
Screening (Visit 1). Subjects who have an absolute contraindi cation for MRI can 
have a Computed Tomography (CT) scan of the brain instead. A follow-up MRI or CT will be performed within 8 da ys prior to Visit 10 (or Earl y Termination) in subjects 
who had a baseline MRI performed at screeni ng. Technical details of the MRI and 
CT scans will be provided in t he Imaging Manual for the study.  
8.15 Modified Hachinski 
The Modified Hachinski ischemic scale will be utilized to differentiate Alzheimerâ€™s 
type dementia from multi-in farct dementia and will be ad ministered at Screening 
(Visit 1). The Modified Hachinski will be adm inistered by a trained clinician with a 
medical background. 
8.16 Height, Weight, and Body Mass Index (BMI) 
Height (cm) and weight (kg) will be m easured and BMI will be calculated only at 
Screening (Visit 1). Only weight will be measured at Visit 10 (or Early Termination). 
8.[ADDRESS_32757] 5 minutes. Vital signs will be recorded once at Screening  (Visit 1), and once at each clinic visit; 
vital signs should be recorded at approximat ely the same time of day on each visit. 
8.18 Columbia-Suicide Severit y Rating Scale (C-SSRS)  
The C-SSRS will be administered by a cert ified rater trained by [CONTACT_33330]-up Phone Calls 
after Visit [ADDRESS_32758] on it (Folstein 1975; 
Colum
bia University Medical Center 2017). 
In the event a subject has  suicidal ideatio n or clinically significant depression, 
appropriate action will be initiat ed at the discretion of the Investigator and/or  Medical 
Monitor.  
Open
 Label Extension: The C-SSRS wi ll be administered at all visits. NOTE: 
Effective 16 February 2021, the OLE portion of the study  was terminated by [CONTACT_429]. 
8.19 Laboratory Assessments 
Follicle stimulating hormone will be m easured at Screening (Visit 1) for 
per
i-menopausal (irregular  menstrual peri ods) or post-menopausal (no menstrual 
period for >12 months) female subjects. A urine pregnancy test will be conducted 
only
 in women of child bearing potential at Screening (Visit 1) and the End of 
Treatment
 or Early Termination Vi sit (Visit 10), and at other visi ts  only if indicated. If  
the urine pregnancy test is positive, a serum pregnancy test will be performed to 
confirm pregnancy. 
Open
 Label Extension: A urine pregnancy test will be conducted only in women of 
child bearing potential at the OLE End of Treatment or Early Termination Visit 
(OLE-6), and at any other visits only if indicated.  NOTE: Effective 16 February 
2021,
 the OLE portion of the study was terminated by [CONTACT_1034]. 
Serology
 will be performed at Screening (V isit 1). Serology will include HCV-Ab, 
HBsAg, and HIV 1 and 2. 
Blood  will be collected at Screening  (Visit 1) to assess ApoE  genotype. 
Serum and whole blood will be collected to measure PBMCs and  biomarkers at 
Visit 2, Visit 7, and Visi t 10 (or Early Termination). 
Safety laboratory tests  will be performed at Screening (Visit 1), Visit 2, Visit 3, 
Visit 4, Visit 5, Visit 6, Visi t  7, Visit 8, Visit 9, and Visi t 10 (or Early Termination) and 
the Safety Follow-up Visit (Visit 11). Safe ty laboratory tests will include chemistry, 
hematology, and urinalysis. See  Appendix A: Clinical Laboratory Analytes for a 
compl ete 
list of analytes.  
Open Label Extension: Safety laboratory te sts will be performed at Visits OLE-1, 
OLE-2, 
OLE-3, OLE-4, OLE-5, OLE-6 (or Early Termination) and OLE-9 (OLE Safety 
Follo
w-Up Visit). NOTE: Effective 16 February 2021, the OLE portion of the study 
was terminated by [CONTACT_1034]. 
For
 more detail refer to the Laboratory Manual.  
Per DMC recommendation (following the No vember  16, 2020 meeting), the following 
increased laboratory analyte testing (liver safety  monitoring) is being implemented: 
ï‚·Every 2 weeks for the initial 12 weeks
Protocol COR388-010  Version 7.0 Page 60 
17 May 2021 
Cortexyme, Inc.  Confidential Information ï‚·Every 3 weeks as of Week 12 through Week 24
ï‚·Every 4 weeks as of Week 24 through Week 32
ï‚·Every 2 weeks for the initial 12 weeks (OLE)
ï‚·Every 3 weeks as of Week 60 through Week 72 (OLE)
ï‚·Every 6 weeks as of Week 72 through Week 84 (OLE)
NOTE: Effective 16 February 2021, the OLE portion of the study wasterminated by [CONTACT_1034]
8.19.1 Monitoring of Laboratory Abnormalities 
All laboratory values will be assessed by t he Investigator to determine clinical 
significance. All abnormal laboratory values c onsidered clinically significant by [CONTACT_33331]. Abnormal 
laboratory values may be considered clinically  significant if they are accompanied by 
[CONTACT_23804]/symptoms and/or require  medical intervention. Abnormal laboratory values 
occurring during the clinical study are to be fo llowed until repeat test results return to 
normal (or baseline), stabilize, or t he subject is lost to follow-up. 
8.20 Urine Drug Screen A urine drug screen will be performed at Screeni ng (Visit 1) and at Visit 2. The 
analytes will include opi[INVESTIGATOR_858], cocaine, amphetamines, and barbiturates. 
8.21 Blood Pharmacokineti c (PK) Evaluations 
At Visit [ADDRESS_32759] 4 hours after the dose 
(at any time between [ADDRESS_32760]-dose). 
At Visit 3, Visit 7, Visit 9, and Visit 10 (o r Early Termination), subjects will return to 
the clinic prior to taking their AM dos e. A pre-dose trough sample will be drawn at 
Visit [ADDRESS_32761] while on-site at the clinic 
at 60 minutes Â± 30 minutes, and at 2 hours Â± [ADDRESS_32762] while 
on-site at the clinic at 3 hours Â± 30 mi n and at 4 hours Â± [ADDRESS_32763] clock time  of each PK sample will be recorded. 
Plasma samples will be quantified for COR388 (and potential metabolites of 
interest). Data will be analyzed by a population pharmacokinetic approach to derive 
COR388 (and potential metabo lites of interest) syste mic exposure metrics. A 
Protocol COR388-010  Version 7.0 Page 61 
17 May 2021 
Cortexyme, Inc.  Confidential Information detailed population PK  analysis plan will be generated and finalized prior to the PK 
analysis being initiated. 
8.22 Cerebrospi[INVESTIGATOR_17106] (CSF) Evaluations 
The LP procedures, and medical care of the subject, will be administered as per 
clinical site standards including imagi ng prior to procedure, if applicable. 
Cerebrospi[INVESTIGATOR_33292] r measurement of bacterial DNA ( Pg) using 
qPCR, biomarkers of AD, and gingipain acti vity. The details of sample collection and 
processing procedures will be provided in  the Laboratory Manual. CSF samples will 
be sent to the central laboratory to be di stributed to a specialty laboratory for 
biomarker analysis. Assessments will be performed up to 7 days pr ior to study drug dosing at Baseline 
(Visit 2) and Visit 10 (or Early Termination). 
8.23 Electrocardiograms (ECGs) 
Standard 12-lead electrocardiograms (E CGs) will be performed at Screening 
(Visit 1), Visit 2, Visit 3, Vi sit 4, Visit 5, Visit 7, Visit 9, Visit 10 (or Early Termination), 
and Visit 11 (Safety Follow-up Visit). The Investigator will review ECGs for any 
changes from baseline. At Visit 2, Visit 3, Visit 7, Visit 9, and Visit 10 (or Early 
Termination), subjects will take their dose on-site and the exact time of the dose 
ingestion will be recorded. The time to maximum plasma concentration of COR388 
(T
max) is approximately 1-1.[ADDRESS_32764] takes their dose of 
study drug on-site, ECGs should be meas ured approximately 1-1.5 hours after 
dosing. At Visit 3 and Visit 7, ECGs will also be performed at trough (prior to dosing). 
ECGs will be reviewed by a cardiologist at the central ECG laboratory to identify any 
abnormalities and verify automatically calc ulated values of RR, PR, QRS, and QTc 
intervals. Clinically significant ECG ev ents and abnormalities will be recorded as 
adverse events. 
Open Label Extension: Standar d 12-lead ECGs will be perform ed at Visits OLE-1, 
OLE-2, OLE-4, OLE-6 (or Early Terminat ion) and OLE-9 (OLE Safety Follow-Up 
Visit). NOTE: Effective 16 February 2021, the OLE portion of the study was 
terminated by [CONTACT_1034]. 
8.24 Safety Monitoring Plan for Potential Drug Induced Liver Injury 
This study is being conducted in compliance with FDA Guidance for Industry on 
Drug-Induced Liver Injury (DILI), which can be accessed at: 
https://www.fda.gov/medi a/116737/download.  
If a study patient experiences any signs or symptoms of hepatic il lness including loss 
of appetite, nausea, vomiting, fever, w eakness, tiredness, right upper quadrant 
tenderness, itching, yellowing of the skin and eyes, light colored bowel movements 
or dark colored urine, or AST or ALT elevation at any time during subjectâ€™s 
Protocol COR388-010  Version 7.0 Page 62 
17 May 2021 
Cortexyme, Inc.  Confidential Information participation in COR388- 010 study, the following sa fety measures will be 
implemented: 
1. Verify previous liver enzymes (ALT, AST) as well as any other liver-related
lab parameters (e.g., INR, alkaline phosphatase, bilirubin (total, direct,
indirect), etc.)
2. Perform detailed review of medical hist ory, especially prior evidence of viral
hepatitis, cholestasis and other associ ated conditions and ensure complete
and accurate data entry in EDC.
3. Perform detailed review of concomitant medications including OTC or herbal
products and ensure complete and accurate data entry in EDC.
4. Contact [CONTACT_33332].
5. Arrange a confirmatory testing within 48-72 hours and repeat until the
abnormality is stabilized or resolved.
6. Between V4/Week 6 â€“ V8/Week 32 and OLE-2/Week 54 â€“ OLE-5/Week [ADDRESS_32765] be performed promptly (stat labs).
If AST or ALT is >2x ULN â€“ perform weekly testing until the abnormality 
resolves. 
If AST or ALT is >3x ULN,  please continue as follows: 
1. Ensure repeat testing (ALT, AST, ALP, GGT, bilirubin, eosinophils (differential
count) 2-3 times weekly until baseline levels are re-established or another
frequency is agreed upon with the medical monitor.
2. Rule out acute viral hepatitis (A, B, C, D, and E) and arrange for an
abdominal ultrasound/MRI/CT.
3. Obtain additional tests to evaluate liver  function, as appropriate (e.g., INR,
direct bilirubin, auto-antibodies, bile salts/acids).
4. Tests for infection with cytomegalov irus, Epstein-Barr virus, and herpes
simplex virus, if fever, ra sh or lymphadenopathy occur.
5. Serum anti-nuclear antibody, anti-smooth muscle antibody, and IgG
concentrations.
6. Consider gastroenterology or hepatology consultations.
7. Please ask the patient to:
ï‚·Give detailed history of any symptom s and prior or concurrent diseases
(please ask with same frequency as  repeated blood tests are performed).
ï‚·Confirm concomitant drug use (incl. non-prescription drugs, herbal
supplements, etc.)
ï‚·Provide information about any alcohol use
Protocol COR388-010  Version 7.0 Page 63 
17 May 2021 
Cortexyme, Inc.  Confidential Information ï‚·Provide information about any exposure to environmental chemical
agents.
Treatment should be stopped if:  
ï‚·ALT or AST >8xULN
ï‚·ALT or AST >5xULN for more than 2 weeks
ï‚·ALT or AST >3xULN and (TBL >2xULN or INR >1.5)
ï‚·ALT or AST >3xULN with the appearance of worsening of fatigue, nausea,
vomiting, right upper quadrant pain or tender ness, fever, rash, or eosinophilia
Rechallenge should not be attempted if:  
ï‚·ALT or AST >5xULN
ï‚·ALT or AST >3xULN and (TBL >2xULN or INR >1.5)
ï‚·ALT or AST >3xULN with the appearance of worsening of fatigue, nausea,
vomiting, right upper quadrant pain or tender ness, fever, rash, or eosinophilia
9 ADVERSE EVENT REPORTING 
Throughout the course of t he study, all adverse events (AEs) will be monitored and 
recorded on an AE eCRF, including the AEâ€™s description, start and end date, 
seriousness, severity, action taken, and relati onship to the investigational product. If 
AEs occur, the first concern will be the safety of the study subj ects. All AEs will be 
followed until resolved or stable and t he outcome documented on the eCRF.  
Open Label Extension: Adverse events will be monitored at all visits and phone 
calls. NOTE: Effective 16 February 2021, the OLE portion of the study was 
terminated by [CONTACT_1034].  
9.1 Definitions and Criteria  
9.1.1 Adverse Events  
Per ICH E2A: An AE is any untoward medica l occurrence in a subject or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily have to have a causal relati onship with this treat ment.  An AE can 
therefore be any unfavorabl e and unintended sign (includi ng an abnormal laboratory 
finding, for example), symptom, or disease temporally a ssociated with the use of a 
medicinal product, whether or not considered related to the medicinal product.  
Medical interventions such as surgerie s, diagnostic procedures, and therapeutic 
procedures are not AEs but the action taken to treat the medical condition.  They 
should be recorded as tr eatment of the AEs. 
Protocol COR388-010  Version 7.0 Page 64 
17 May 2021 
Cortexyme, Inc.  Confidential Information 9.1.2 Serious Adverse Events  
A serious adverse event (SAE) or reaction is any untoward medical occurrence that 
at any dose:  
â€¢ Results in death
â€¢ Is life-threateningâ€¢ Requires inpatient hospi[INVESTIGATOR_32957]
â€¢ Results in persistent or signifi cant disability or incapacity
â€¢ Is a congenital anomaly or birth defectâ€¢ Is an important medical event (e.g., in tensive treatment in an emergency room
or at home for allergic bronchospasm; bl ood dyscrasias, or convulsions that do
not result in hospi[INVESTIGATOR_059]; or dev elopment of drug dependency or drug abuse;
malignancy tumors [histologically different from pr imary tumor])
Note: The term â€œlife-threateningâ€ in the defin ition of â€œseriousâ€ refers to an event in 
which the subject was at risk of death at the ti me of the event; it do es not refer to an 
event that hypothetically might have caused death if it were more severe.  
In this study, hospi[INVESTIGATOR_33293] 24-hours in duration. 
Medical and scientific judgem ent should be exercised in deciding whether expedited 
reporting is appropriate in other situations, such as important medical events that 
may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_33294]. These should al so usually be considered 
serious.  
Examples of such events are intensive treatment in an emergency room or at home 
for allergic bronchospasm; blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug dependency or drug abuse.  
The term â€œsevereâ€ is often used to describe t he intensity (severity) of a specific event 
(as in mild, moderate, or se vere); the event itself, however, may be of relatively 
minor medical significance (such as a seve re headache). This is not the same as 
â€œserious,â€ which is based on the outcome  or action associated with events, as 
described above. Seriousness (not severi ty) serves as a guide for defining 
regulatory reporting obligations.  
9.1.3 Unexpected Adverse Drug Reactions  An unexpected adverse drug reaction (ADR) is a reaction for which the nature or 
severity is not consistent with the applicab le product information (I B, Package Insert 
for marketed products). Until product info rmation is amended, expedited reporting is 
required for additional occurrenc es of the reaction. Repo rts that add significant 
Protocol COR388-010  Version 7.0 Page 65 
17 May 2021 
Cortexyme, Inc.  Confidential Information information on specificity or severity of a known, already documented SAE constitute 
unexpected events. For example, an event more specific or more severe than 
described in the IB would be cons
idered "une xpected.â€ Specific examples would be 
(a)acute renal failure as a labeled ADR with a subsequent new report of interstitial
nephritis and (b) hepatitis with a firs
t report of fulminant hepatitis.
Guidance on reporting AEs and SAEs is described in Section 9.2. 
9.1.4 Abnormal Laboratory Values  
Any abnor
mality in a laboratory value that is new in onset or which has worsened in 
severity or frequency from the baseline condition and  meets 1 of the following 
criteria will be recorded on t he AE pages of the eCRF:  
â€¢ Requires therapeutic intervent ion or diagnostic tests;
â€¢ Leads to discontinuation of  investigational product;
â€¢ Has accompanying or inducing symptoms or signs; and/or
â€¢ Is judged by [CONTACT_33333].
9.1.5 Assessing Intensit y and Relationship  
All AEs will be assessed on 2 descriptive parameters: intensity and relationship to 
the investigational product: 
ï‚·Intensity refers to the severity of an event and references impact on a subjectâ€™s
functioning.
ï‚·Relationship refers to the likelihood that the event being assessed was caused
by [CONTACT_7198].
Intensity  
Each AE will be classified according to the following criteria: Mild:  The AE does not interfere in a significant manner with the 
subjectâ€™s normal level of functioning.  
Moderate:  The AE produces some impairment  of functioning but is not 
hazardous to the subjectâ€™s health.  
Severe:  The AE produces significant impairment of functioning or 
incapacitation and is a definit e hazard to the subjectâ€™s 
health.  
Relationship 
Protocol COR388-[ADDRESS_32766] plausible association. 
Not related: No causal relationshi p exists between the investigational 
product and the AE, but an obvious alternative cause exists, e.g., the subjectâ€™s underlying medical condition or concomitant therapy.  
Possibly related: A connection with the adm inistration of the investigational 
product appears unlikely but cannot be ruled out with certainty. An AE may be consid ered possibly related if or 
when it meets 2 of the followi ng criteria: (1) it follows a 
reasonable temporal sequence fr om administration of the 
investigational product; (2) it could not readily have been produced by [CONTACT_423]â€™s clinical state, environmental or toxic factors, or other modes of therapy administered to the subject; or (3) it follows a known pattern of response to the investigational product.  
Related: There is a reasonable/plausible possibility that the AE 
may have been caused by [CONTACT_7198]. 
When assessing the relationship to the invest igational product, the following criteria 
will be considered:  
â€¢ Positive re-challenge (restart of IP  dosing following dosing interruption); 
Note: In this study re-challenge of IP will not be allowed if IP dosing was discontinued for IP-related safety reasons e.g. when a DILI protocol is 
triggered and/or due to an AE that was assessed as possibly or probably 
related to the IP. 
â€¢ Positive de-challenge (resolution upon stoppi[INVESTIGATOR_33295], in absence of other intervention or treatment); 
â€¢ Known class effect; 
â€¢ Biological plausibility; and â€¢ Lack of alternative explanation â€”concomitant drug or disease. 
9.2 Reporting Procedures and Requirements  
9.2.1 Adverse Events  Adverse events (AEs) occurring from when t he subject signs the ICF until the last 
study event will be recorded. Any AEs occurri ng before the start of  treatment (i.e., 
before the first dose of the investigationa l product) will be recorded in the medical 
Protocol COR388-[ADDRESS_32767] scheduled follow-up 
visit and considers the event possibly related or related to prior  study treatment, the 
Investigator should report it to the Sponsor / Contract Research Organization (CRO). 
The Investigator should report all AEs on the AE page(s) of the eCRF and source 
documents, regardless of seriousness, seve rity, and causality. Whenever possible, 
an AE
 will be reported using a diagnostic term, (e.g., â€œc ommon coldâ€  or â€œupper  
respi[INVESTIGATOR_33296]â€ rather than â€œrunny  nose, cough, mild feverâ€) and should be 
described with the attributes  described in Section 9.1.5. 
9.2.2 
Serious Adverse Events 
Each AE will be assessed to determine whether it meets seriousness criteria 
(Section 9.1.2). If the AE is  considered serious, the Investigator should report this 
event to the Sponsor and CRO as outlined be low and also to the IRB/IEC according 
to its standard operat ing procedures.  
If the Investigator detects an SAE in a study subject after the last scheduled 
follow-up
 visit, and considers the SAE relate d or  possibly related to prior study 
treatment, the Investigator should report it to the Sponsor and CRO.  
All information about SAEs will be collect ed a nd reported via the SAE form and sent 
by e-mail message or facsimile (contact [CONTACT_33334]). The Investigator should send the initial report within 24 hours 
of becoming aware of the SAE. At minimum, the initial report should include the 
following  
information:   
ï‚·Event;
ï‚·Study code;
ï‚·Subject number, initials, and date of birth;
ï‚·Investigational product; and
ï‚·Reporter name [CONTACT_3669] [CONTACT_3031].
In the case of a â€œminimum r eportâ€ (one that solely comp rises the information bulleted 
above), a more detailed follow-up report shoul d be sent as soon as more information 
becomes available, but no la ter than 7 calendar days afte r the date of the initial 
report. Each SAE should be followed up until  resolution or stabilization and for 
reported deaths, the Investigator should supply Sponsor/ CRO and the IRB/IEC with 
any additional requested information (e.g., autopsy reports and terminal medical reports).  
The original SAE form should be kept at the study site. The Sponsor or its 
representative will be responsible for det ermining and in turn, reporting SAEs to 
regulatory authorities according to the applicable regulator y requirements.  
Protocol COR388-[ADDRESS_32768] becomes pregnant during the study, the Investigator will notify 
Sponsor/CRO immediately following 9.1.5 confirmation. The Investigator will also: (1)
notify the subjectâ€™s physician that
 the subject may have been treated with COR388 
HCl and (2) follow the progress of the pregnancy to term and document theoutcome 
of the pregnancy. Subjects who
 become pregnant during the study will not be eligible 
for any further study treatments. Pregnancy outcome information should be 
forwarded to Sponsor/CRO when availa
ble. The Investigator and Cortexyme  will
determine, on a case-by-case basis, whether the subject will continue in the study
and, if so, which stud
y measures will be collected.
9.[ADDRESS_32769]â€™s clinical status. 
In the event of a suspected overdose, and if
 in the opi[INVESTIGATOR_33297], the Invest igator or treating 
physician should:
 
ï‚·Contact [CONTACT_27465].
ï‚·Have the subject come to the clinic as soon as possible to draw blood for
clinical laboratory testing.
ï‚·Closely monitor the subject for AEs/SAEs and laboratory abnormalities
and ensure appropriate clinical managem ent. Overdose in the absence of
other AEs will not be reported as an AE in its own right.
ï‚·Document the quantity of  the excess dose, as well as the time of
administration of the ov erdose, in the eCRF.
ï‚·Subjects should be observed closely in a medical facility whereappropriate supportive care is  available, if required.
Protocol COR388-[ADDRESS_32770] operating pr ocedures of the Sponsor  and of the laboratory 
performing the analysis, in compli ance with relevant regulation. 
11 STATISTICAL AND ANALYTICAL PLANS 
11.1 General Considerations 
The statistical analyses  are described in this section. Further details will be provided 
in the Statistical Analy
sis Plan (SAP), which will be finalized prior to database lock 
and unblinding for the interim analysis.  Any deviations from the analyses described 
belo
w will be includ ed in the SAP.   
All efficacy and safety measures over the course of the study will be presented.  
Continu
ous data will be summari zed by m eans, standard deviations (SDs), medians, 
maximum, minimum, and number of subjects .  Categorical data will be summarized 
by [CONTACT_33335]. 
11.[ADDRESS_32771] an adaptive design that a llows for potential adjustment in sample 
size and evaluation of efficacy based on t he results of a planned interim analysis.  
An unblinded interim analysis will be c onducted by a firewalled independent 
statistician (all clinical tr ial personnel will remain blinded) when approximately [ADDRESS_32772] completed the Week 24 visit.   Approximately 573 subjects 
are planned to be randomized 1:1:1 per treatment group (191 per treatment group) 
assuming approximately 10% will drop out prior to 48 weeks.  Due to the planned 
interim analysis, adjus
tments will be made to the alpha level used in the final 
analys
is to control for overall Type I error.  The final crit erion for efficacy to be used 
at the interim and final analysis depends on when the interim analysis occurs. The 
Lan-DeMets method modified according to Chen et al. (2004) to account for 
correlation between endpoints used at the interim and final analyses will be used to 
calculate the level of significance for each analysis. As originally planned, with 573 
subjects randomized, an expected 10% disc ontinuation rate, and a single primary 
outcome, a total of 172 subjects per treat ment group would prov ide approximately 
90% power to detect a 2.5-point differ ence between the active treatment group 
compared to placebo with respect to change from baseline on the ADAS -Cog 11, 
assuming a standard deviation of 7.1, respecti vely at a significance level (alpha) of 
0.[ADDRESS_32773] deviation of 10.5, providing appr oximately 95% power on this outcome 
Protocol COR388-010  Version 7.0 Page 70 
17 May 2021 
Cortexyme, Inc.  Confidential Information measure, with approxim ately 90% power for the overal l co-primary outcomes, 
depending on their correlation.   
These results assume that [ADDRESS_32774] completed the Week 24 visit, 
then a significance lev
el of 0.005 will be used for the interim analysis and a 
significance level of approximately 0.0456 will be used for the final analysis.  As 
discussed by 
[CONTACT_33336] 2004, the sample size re-estimation procedure based on 
promising zone will not inflate the type I error and no statistical adjustment is 
necessary.  However, the adjuste
d alpha at the end of the study will be based on the 
new sample size at the final analysis. 
11.3 Final Analysis 
11.3.1 Analysis Populations 
ï‚·Intent-To-Treat Population (ITT): The ITT populat ion will include all subjects who
are randomized regardless of whether or not they took study drug. This
population will serve as the basis for all efficacy analyses. When change from
baseline is assessed, subjects will be included in the analysis only if both a
baseline and a postbaseline measure are available.
ï‚·The Per Protocol population (PP): The PP population will include all ITT subjects
who do not have any major protocol deviati ons that would affe ct efficacy (e.g.,
<80% treatment compliance, taking a prohibited medication).  Major protocoldeviations will be reviewed and determi ned prior to unblinding.  The
PP population will be used for suppor tive sensitivity analyses.
ï‚·Safety Population: The Safety population will include all subjects who receive at
least one dose of study drug. Safety analyses will be performed using the Safetypopulation, and subjects will be analyzed according to the treatment they actuallyreceive.
11.3.2 Efficacy Analysis 
[IP_ADDRESS] Primary Efficacy Analysis 
The co-primary endpoints are the mean c hange from baseline in  ADAS-Cog 11 at 
the end of the study (average of W eeks 40 and 48), and the mean change from 
baseline in the Alzheimerâ€™s Disease Cooperati ve Study â€“ Activities of Daily Living 
(ADCS-ADL) at the end of the study (average of Weeks 40 and 48).   
Each of the coprimary endpo ints will be analyzed using a mixed-effects model for 
repeated measures (MMRM) with SAS PROC MIXED to compare change from 
baseline for COR388 HCl vs placebo.  T he MMRM model will include treatment 
group, study visit, site/country, treatment gr oup by [CONTACT_33337], and baseline MMSE (average of  the last two non-missing assessments 
Protocol COR388-[ADDRESS_32775] dose of the IP), ApoE4 status, and 
acetylcholinesterase inhibitor
 and/or mema ntine usage at baseline as factors with 
baseline score as a covariate using the ITT population. The analysis will be based 
on unstructured covariance matrix to model the within-subject errors. A Kenward-
Roger
 approximation will be used for the denominator degrees of freedom.   
Summary
 statistics (n, mean, standard dev iation, minimum, median, and maximum) 
will be presented for the observed values  for each of the coprim ary endpoints at 
each time point  for the ITT population,  including weeks 40 and 48 separate as  well 
as
 averaged.  Summary statistics will also b e presented for the change from 
baseline values to each postbaseline time point as listed above.   
The Type I error for the interim  and final  analysis will be adjusted using the Lan-
DeMets spending function. Detailed of the adjustment is presented in 
Section [IP_ADDRESS] and in the SAP. 
Treatment comparisons of
 40 mg and 80 mg COR388 HCl to placebo will be 
adjusted using Benjamini-Hochberg multiplicity adjustment procedure (Benjamini 
and
 Hochberg, 1995 and Benjamini and Yekutieli, 2001).  Both treatment 
comparisons , 40 mg (low dose) and 80 mg COR388 HCl (high dose) to placebo are 
considered of equal interest.  
[IP_ADDRESS].1 Sensitivity
 Analyses 
The following sensitivity analyses will be per formed on each of the co-primary 
endpoints:
 
ï‚·Repeat above analysis using the PP population.
ï‚·Impute missing values using a last z-score carried forward method
(converted back to the original sc
ale) and analyze the primary endpoint
(Average of Weeks 40 and 48 only) using analysis of covariance (ANCOVA)
with fixed effects of trea
tment group, ApoE4 status, acetylcholinesterase 
inhibitor and/or memantine usage, site/country and baseline MMSE with 
baseline score as a covariate.
ï‚·Pattern mixture model:
The pattern-mixture model approach uses a control-based pattern imputation
(Ratitch and Oâ€™Kelly, 2011). With this approach, subjects who discontinued
from the COR388 HCl 80 mg or COR388 HCl 40mg treatment group will be 
assumed to follow a similar outcome trajectory as subjects from the placebo 
(control) arm and subjects who discont
inued from placebo (control) treatment
are modeled as completers within thei
r own arm (MAR within control arm).
That is, the imputation model for the missing observations in the active
treatment groups are constructed not from the observed data in the
corresponding 
active treatment group but rather from the observed data in the
placebo treatment group. This model is also the imputation model that will be 
used to impute missing observations in the placebo treatment group. This will
Protocol COR388-010  Version 7.0 Page 72 
17 May 2021 
Cortexyme, Inc.  Confidential Information be implemented by [CONTACT_33338]Â® PROC 
MI with the option nimpute=5. 
Pattern mixture model tends to overestima te the already very large variability 
in Alzheimerâ€™s disease data, these model results are likely to be much less 
able to discriminate treatment differences  than the primary model. The results 
of this imputation method wil l primarily be used to assess the potential bias of 
the main model estimates due to dr opout by [CONTACT_33339]. 
Additional subgroups including g ender, demographic, and other baseline 
characteristics may be performed.  Furt her details will be given in the SAP. 
[IP_ADDRESS] Secondary Endpoint Analyses 
Secondary endpoints will be analyz ed for the ITT population only. 
The analysis of secondary endpoints will use t he same methodology as that for the 
primary endpoint analysis but adjusting for corresponding baseline value as a 
covariate. Treatment com parisons of 40 mg and 80 mg COR388 HCl to placebo for 
the secondary endpoints at 24-week or 48-w eek will be performed only if both co-
primary endpoints compared to placebo are statistically  significant. Otherwise, 
secondary endpoints will be presented using descriptive statistics  
[IP_ADDRESS] Multiplicity 
To control for type I error, for the interi m and final analysis will be adjusted using the 
Lan-DeMets spending function.  If the study  does not stop at the interim analysis 
(i.e., [ADDRESS_32776]-SB as co-p rimary endpoints) for overwhelming 
efficacy or futility, the study will retain its original design and the final analysis will be 
based on 48 weeks of treatment with AD AS-Cog and ADCS-ADL as co-primary 
endpoints. Because of the changes in co -primary endpoint at 48 weeks (i.e., CDR-
SB 24-week replaced by [CONTACT_33340]-ADL at 48-week and ADAS-Cog 24-week replaced 
by [CONTACT_33341]-Cog 48-week), the Lan-DeMets correction for sequential analysis will be 
further adjusted as described in Chen et al., (2014). This adjustment will account for 
the correlation between the outcomes and time points. The boundaries will be 
calculated to account for the change in ti ming of evaluation and endpoint and the 
more conservative boundary will be used for final analysis at 48-week.   
At both the interim analysis at [ADDRESS_32777] for 
comparison between placebo and each of  the two doses, Benjamini-Hochberg 
multiplicity adjustment procedure (Benjamini and Hochberg, 1995 and Benjamini and  
Yekutieli, 2001 ) will be used.  Both treatment comparisons, 40 mg (low dose) and 80 
mg COR388 HCl (high dose) to placebo ar e considered of equal interest.   
Treatment comparisons of  40 mg and 80 mg COR388 HCl to placebo for the 
secondary endpoints at 24-week or 48-w eek will be performed only if both co-
Protocol COR388-010  Version 7.0 Page 73 
17 May 2021 
Cortexyme, Inc.  Confidential Information primary endpoints compared to placebo are statistically significant at the level of 
approximately 0.005 or 0.0456 for the in terim analysis and final analysis, 
respectively. Otherwise, secondary endpoi nts will be presented using descriptive 
statistics.  
[IP_ADDRESS] Exploratory Endpoints 
Exploratory endpoints will be analyzed for the ITT population only.  No adjustment 
for multiplicity will be done.   
Further details of the analyses to be performed will be provided in the SAP. 
11.3.3 Safety Analysis 
[IP_ADDRESS] Adverse Events 
Adverse events will be coded by [CONTACT_9560] (PT) using the Medical Dictionary 
for Regulatory Activities (MedDRA) classification.  
A treatment-emergent adverse event (TEAE) is defined as any AE that has an onset 
on or after the first dose of study drug,
 or any pre-existing condition that has 
worsened on or after the first dose of study drug. The incidence of TEAEs, 
treatment-related TEAEs, SAEs includ
ing de aths, TEAEs that lead to discontinuation 
of investigational product, and TEAEs by [CONTACT_33342], PT, an
d treatment group.   
To assess the potential for abuse associated with the administration of 
COR388 HCl, a systematic review of TEAE terms suggestive of the potential for 
abuse will be conducted for all clinical studies
 in subjects who received at least 1 
dose of COR388 HCI and a summary of this information will be included in the 
regulatory submission. 
As a general framework for data collection and analysis we 
will use the overall abuse flag terms in the FDA Guidance (2017). 
Since the target patient population are elderly, have subs tantial comorbidity and are 
often on other medications, a careful 
assessment and documentation of adverse 
event causality will be made in order to ensure that false positive TEAE signals for 
abuse are not generated. For example, di zziness and sedation or sleepi[INVESTIGATOR_33298]â€™s disease. 
Since to date no abuse related TEAE attributable to COR388 HCl have occurred, 
focus will be on a restricted set of index events for which narratives will only be 
prepared where the causality relationship to
 COR388 HCl is proba ble or definite. 
Information included in the narratives will consist of time to onset/offset, time course 
of severity, all concurr
ent events, concu rrent medications, and time of onset of 
events relative to ingestion of COR388 HCl. 
Protocol COR388-010  Version 7.0 Page 74 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 The index TEAEs will include: 
â€¢ Any reports of altered perception or hallucinations â€¢ Dizziness â€¢ Euphoric mood â€¢ Feeling drunk â€¢ Feeling of relaxation â€¢ Sedation â€¢ Somnolence 
[IP_ADDRESS] Laboratory Data 
Laboratory data (hematology, blood chemistry, and uri nalysis parameters) will be 
presented for each treatment group using descriptive statistics, including mean and mean change from baseline values at eac h scheduled time point. Shift tables will 
display numbers of subjects with norma l/abnormal values at baseline versus 
post-treatment. The frequency of labor atory abnormalities will be tabulated. 
By-subject data listings will flag laboratory va lues that are outside normal reference 
ranges or markedly abnormal findings. 
[IP_ADDRESS] Vital Signs  
Descriptive statistics for observed values  and change from baseline in vital sign 
parameters [blood pressure (systolic and di astolic), body temperature, pulse, and 
respi[INVESTIGATOR_697]] will be presented by [CONTACT_3232].  
[IP_ADDRESS] Electrocardiograms 
Descriptive statistics for observed values  and change from baseline in (continuous) 
ECG parameters (e.g., RR, PR , QTc) will be presented by [CONTACT_33343].   
Shift tables in relation to overall inte rpretation (Normal, Abnormal Not Clinically 
Significant [NCS] and Abnormal Clinically Significant [CS] ) from baseline to each 
post-baseline visit will be presented.  
[IP_ADDRESS] Other Safety Assessments 
The C-SSRS will be summarized at each vi sit by [CONTACT_33344]. 
Abnormal physical examinations and MRI results will be summarized descriptively 
by [CONTACT_3232]. 
11.3.[ADDRESS_32778] 24 weeks of treatment. Both 
treatment comparison s will be assessed at the interim analysis: 40 mg COR388 HCl 
and 80 mg COR388 HCl vs. placebo for the tw o co-primary endpoints (i.e., mean 
change from baseline in ADAS-Cog [ADDRESS_32779]-SB 
at Week 24). Analyses will be performed as spec ified in the approved final study SAP. 
The DMC should return to the Sponsor one of four recommendations as follows: 
Stop the study early for overwhelming efficacy defined as p<0.005 adjusted for
multiplicity using the 
Benjamini-Hochberg procedure for both ADAS-Cog 11 and
CDR-SB in favor of either 40 mg COR388 or 80 mg COR388 HCl over placebo;
Stop either or both arms (stoppi[INVESTIGATOR_007] b oth arms would m ean stoppi[INVESTIGATOR_10098])
early for futility defined as p<0.[ADDRESS_32780]-SB in favor of
placebo over active dose(s), and the other endpoint for the same dose is
directionally favoring placebo;
Continue 
with no sample size adjustment; or
Continue with an appropriate sample size adjustment
Interim comparative data will be most se curely protected from inadvertent or 
inappropriate access by [CONTACT_1034]. Sponsor will remain blinded to all information except the DMC recommendations.   
11.3.6 Pharmacokinetic Analysis 
Plasma levels of COR388 wi ll be determined from blood samp les collected at Visit 2, 
Visit 3, Visit 7, Visit 9, and Visit 10 (or Early Termination). 
Descriptive statistics (sample size, mean,  SD, minimum, median, and maximum) will 
be calculated for all results. Geometric me an and geometric coefficient of variation 
(CV)% will also be calculated for PK parameters. 
12 STUDY MANAGEMENT 12.1 Regulations and Guidelines 
The study will be performed in accordance with this protocol, [LOCATION_002] IND 
regulations (21 Code of Federal Regulation s [CFR] 312) or local national laws (as 
applicable), ICH guidelines for Good Clinical Practice, and the most recent 
Protocol COR388-010  Version 7.0 Page 76 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 guidelines of the Declaration of Helsinki. These guidelines are on file at the Sponsor 
and/or CRO . 
12.2 Institutional Review Boar d/Independent Ethics Committee 
Conduct of the study must be approved by [CONTACT_33345]. 
Approval is required for the study protocol, investigatio nal drug brochure, protocol 
amendments, ICFs, subject information sheets, and advertising materials. No 
investigational product will be shipped to a site until written IRB/IEC authorization 
has been received by [CONTACT_33346].  
12.3 Discontinuation of th e Study by [CONTACT_33347]. In particular,  a site that does 
not recruit at a reasonable rate may be di scontinued. Should t he study be terminated 
and/or the site closed for whatever reas on, all documentation and investigational 
product pertaining to the study must be retur ned to the Sponsor or its representative.  
12.4 Study Documentation 
By [CONTACT_2960] a copy of Form FDA 1572 or other  country-specific regulatory forms, the 
Principal Investigator [INVESTIGATOR_33299]/she has received a copy of the IB on 
COR388 HCl and assures the Sponsor that he/she will comply with the protocol and 
the provisions stated in Form FDA 1572 and other country-specific forms. No 
changes in this protocol can be made without the Sponsorâ€™s written approval.  
12.5 Study Monitoring and Auditing 
This study will be monitored for quality assurance at all stages of its development by 
[CONTACT_33348]. 
Monitoring will include remote (virtual) dat a reviews, personal visits, and telephone 
communication to assure that the invest igation is conducted according to the 
protocol, standard operating procedures, Guidelines of Good Clinical Practice, and applicable regulatory requirem ents. Quality control proc edures will be applied to 
each stage of data handling to ensure t hat all data are re liable and have been 
processed correctly. On-site and remote re view of eCRFs will include a review of 
forms for completeness and clarity, and consistency with source documents 
available for each subject. Note that a va riety of original documents, data, and 
records will be considered as source documents in this trial.  Procedures for handling 
source documents remotely will be described in the Clinical Monitoring Plan. The eCRF itself is not to be used as a s ource document under any circumstances.  
Medical advisors and Clinica l Research Associates (CRAs) or assistants may 
request to witness subject evaluations o ccurring as part of this protocol. The 
Investigator and appropriate personnel wi ll be periodically requested to attend 
Protocol COR388-010  Version 7.0 Page 77 
17 May 2021 
Cortexyme, Inc.  Confidential Information meetings/workshops organized by [CONTACT_33349]. The study may be subject to audit by [CONTACT_33350]. If such an audit occurs, the Inve stigator must agree to allow access to 
required subject records. By [CONTACT_12570], the Investigator grants permission 
to personnel from the Spons or, its representatives, and appropriate regulatory 
authorities, for remote and on- site monitoring of all appropr iate study documentation, 
as well as on-site review of the procedur es employed in eCRF generation, where 
clinically appropriate. 
12.6 Data Monitoring Committee 
An independent Data Monitoring Committee (DMC) will be established to review 
accumulating 
study data to monitor the safety of subjects enrolled in COR388-010 
on an ongoing basis and review the interi
m analysis (see Section 11.3.5).  All 
members will be independent of the study (e.g., not a participating site employee, 
Cortexyme employee, etc.). 
The DMC will review data on a regular basis.
  After reviewing the safety data, the 
DMC may make a recommendation to continue the study  with or without 
modification or terminate the study.  The DMC Charter defines all DMC 
responsibilities, 
functions, membership, meeting structure, communications , DMC 
SAP, and rules for decision making. 
12.[ADDRESS_32781] stringent authority. The 
Investigator should take measures to prev ent accidental or prem ature destruction of 
these documents.  
12.8 Use of Study Findings 
By [CONTACT_33351], the Investi gator agrees to the us e of results of the 
study for the purposes of national and inter national registration. If necessary, the 
authorities will be notified of the Investigatorâ€™s name, address, qualifications, and 
extent of involvement. Reports covering c linical and biometric as pects of the study 
will be prepared by [CONTACT_33352]. 
12.9 Publications 
As a multicenter trial, the Sponsor intends to publish clin ical data from all centers 
participating in the investi gation. A publication committee selected by [CONTACT_33353] r their comments. In 
conformity with the Uniform Requirements for Manuscripts  Submitted to Biomedical 
Journals published by [CONTACT_33354] J ournal Editors (see 
Protocol COR388-010  Version 7.0 Page 78 
17 May 2021 
Cortexyme, Inc.  Confidential Information discussion in Kassirer & Angell, 1991), investigators whose contribution consists 
solely in the collection of data will not be named individually as authors. Rather, 
those investigators will receive a collective authorship as the â€œCOR388 Study Groupâ€ 
and will be identifie d in a note.  
Individual investigators 
and/or their asso ciates subsequently may publish additional 
findings of this study in scientific journal s or present them at scientific meetings, 
provided that the Sponsor is given ampl e opportunity to review any proposed 
abstract, 
manuscript, or slide presentation before its submission. This review is 
required to ensure that the Sponsor is aware of all written and oral presentations of 
the data and does not imply any editorial review
 or restriction of the contents of the 
presentation or use. 
12.[ADDRESS_32782] numbers.  
As required by [CONTACT_33355] , the Investigator will allow Cortexyme and/or the 
CRO CRA access to all pertinent medical record s in order to allow for the verification 
of data gathered in the eCRFs
 and for the review of the data collection process. The 
FDA (or other regulatory authority) may al so request access to all study records, 
including source documentation for inspection. 
As applicable, in accordance with Health Insurance Portability and Accountability Act 
(HIPAA) and associated privacy regulat ions, a subject authorization to use 
personally identifiable health infor
mation may be required from each subject prior to 
research activities. This authorization document must clearly specify what parties will 
have acces
s to a subjectâ€™s personal health inf ormation, for what purpose, and for 
how long. 
12.11 Amendments to the Protocol 
Any amendments to the study protocol will be communicated to the investigators by 
[CONTACT_33356]. All protocol amendments will undergo the same review and 
approval process as the original pr otocol. A protocol amendment may be 
implemented after it has been approved by  [CONTACT_1201]/IEC, and, where appropriate, 
competent regulatory authority approval prior to impl ementation, unless immediate 
implementation of the change is necessary for subject safety. In this case, the 
situation must be documented and reported to  the IRB within [ADDRESS_32783] be fully documented in the source documentation 
and in a protocol deviation log. 
12.12 Case Report Form Completion 
Electronic CRFs (eCRFs) will be employed for this study.  Completed eCRFs for this 
study will be forwarded to the Sponsor or its representative, where editing and 
Protocol COR388-[ADDRESS_32784] version of the Medical Dictionary for Regulatory Activities (MedDRA).  
Concomitant medications will be coded using t he latest version of the World Health 
Organizatio
n Drug Dictionary.  Data m anagement details will be outlined in a 
separate data managem
ent plan. 
12.13 Removal of Subjects fr om Therapy or Assessment 
Liver Safety Monitoring (laboratory analyte testing) must be performed at each study 
visit within the prespecified visit window (see Table 1 and Table 2, Schedule of 
Evaluations) OR the study dr ug dosing must be temporarily halted until the testing is 
done.  
Subjects who discontinue IP dosing for IP-related safety reasons will not be 
permitted to resume IP treatment and must be followed until the safety concern (e.g. 
transaminase elevations) or an existing AE has stabilized or resolved/returned to 
baseline. At that time subjectâ€™s partici pation in the study mu st be terminated early 
and V10/ET procedures must be performed. Subjects should remain in the study 
through final 6-weeks safety follow up perio d which ends with a final study visit. 
A subject will be considered to have comple ted the study when he or she completes 
Visit 11. If a subject is discontinued at any  time after randomization into the study, 
the Investigator will make every effort to follow the subject and complete the 
Visit 10/Early Termination assessments.  
A termination electronic case report form (eCRF) page shoul d be completed for 
every subject who receives investigati onal product, whether or  not the subject 
completes the study. The reason for any ear ly discontinuation should be indicated 
on this form. The primary reason for a s ubject discontinuing early should be selected 
from the following st andard categories of early termination:  
â€¢Adverse Event (Adverse Reaction) : Clinical or laboratory events occurred that,
in the medical judgment of the Investigator for the bes t interest of the subject, 
are grounds for discontinuation. Th is includes serious and nonserious 
adverse events (AEs) regardless of rela tion to the investigational product.  
â€¢Death: The subject died.
â€¢Withdrawal of Consent : The subject desired to  withdraw from further
participation in the study in the absence of an Investigator-determined 
medical need to withdraw. If the subj ect gave a reason for withdrawing, it 
should be recorded in the eCRF.  
Protocol COR388-010  Version 7.0 Page 80 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 â€¢ Protocol Violation : The subjectâ€™s findings or conduct failed to meet the protocol 
entry criteria or failed to adhere to the protocol require ments (e.g., drug 
noncompliance, failure to return for defined number of visits). The violation 
necessitated early discontinuation from the study.  
â€¢ Lost to Follow-Up : The subject stopped coming for visits and study personnel 
were unable to contact [CONTACT_423].  
â€¢ Other : The subject was discontinued for a r eason other than those listed above, 
such as theft, loss of investigationa l product, or termination of study by 
[CONTACT_2728]. 
12.14 End of the Study 
For regulatory purposes, the definition of  the end of the study is database lock. 
  
Protocol COR388-010  Version 7.0 Page 81 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 13 REFERENCES 
Benjamini, Y; Hochberg, Y. "Controlling t he false discovery rate: a practical and 
powerful approach to multiple testing" (P DF). Journal of the Royal Statistical 
Society, Series B. 1995; 57 (1): 289â€“300. MR 1325392. 
Benjamini, Y, Yekutieli, D. "The control of the false discovery rate in multiple 
testing under dependency" (PDF). Annals of Statistics. 2001; 29 (4): 1165â€“
1188. doi:10.1214/aos/ [PHONE_528]. MR 1869245. 
Chen, LM, Ibrahim, J.G; Chu, H.  Flexible Stoppi[INVESTIGATOR_33300]. J Biopharm 
Stat. 2014; 24(4): 817â€“833. Chen YH, DeMets DL, Lan KK. Increasing the sample size when the unblinded 
interim result is promisi ng. Stat Med.  2004;23:1023-1038. 
Columbia University Medical Center. Columbia-Suicide Severity Rating Scale 
(C-SSRS). Center for Suicide Risk A ssessment. http://cssrs.columbia.edu/. 
Accessed 15 November 2017. 
Dmitrienko A, Millen BA, Brechenmacher T, Paux G. Development of 
gatekeepi[INVESTIGATOR_33301]. Biom J. 2011;53(6):875-
893. 
Folstein MF, Folstein SE, McHugh PR. â€œMi ni-mental stateâ€. A practical method 
for grading the cognitive state of patient s for the clinician. J Psychiatr Res. 
1975;12:189-198. Hughes CP, Berg L, Danzinger WL, Coben LA, Martin RL. A new clinical scale 
for the staging of dementia. Br  J Psychiatry. 1982;140:566-572. 
Ito K, Corrigan B, Romero K, et al. Understanding placebo responses 
in Alzheimer's disease clinical trials  from the literatur e meta-data and CAMD 
database. J Alzheimers Dis. 2013;37(1):173-183.  
Jennison, C; Turnbull, BW. Group S equential Methods with Applications to 
Clinical Trials. Chapman & Hall/CRC, 2000, pp 205-208. 
Kassirer JP, Angell M. On authorsh ip and acknowledgments. N Engl J 
Med. 1991;21;325(21):1510-1512. McKhann GM, Knopman DS, Chertkow H, et  al. The diagnosis of dementia due 
to Alzheimer's disease: recommendations  from the National Institute on Aging-
Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's 
disease. Alzheimers Dement. 2011;7:263-269. 
Protocol COR388-010  Version 7.0 Page 82 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 Mohs RC, Cohen L. Alzheimerâ€™s Disease Assessment Scale (ADAS). 
Psychopharmacol Bull. 1988;24:627-628. 
Wattmo C, Minthon L, Wallin Ã…K. Mild versus moderate stages 
of Alzheimer's disease: three-year out comes in a routine clinical setting of 
cholinesterase inhibitor therapy. Alzheimers Res Ther. 2016;8:7.  
  
Protocol COR388-010  Version 7.0 Page 83 
17 May 2021 
Cortexyme, Inc.  Confidential Information 
 APPENDIX A: CLINICAL LABORATORY ANALYTES  
Safety Chemistry Panel 
Alanine transaminase Albumin 
Alkaline phosphatase Amylase 
Aspartate transaminase Bicarbonate 
Gamma- glutam yl transferase Calcium 
Blood urea nitro gen Creatinine kinase 
Chloride Estimated glomerular filtration rate 
Creatinine Glucose 
Inorganic phosphorus HbA1c 
Lipase Lactate dehydrogenase 
Sodium Potassium Total protein Total bilirubin 
Uric acid Direct bilirubin 
Ma
gnesium Indirect bilirubin 
 
Hematology 
White blood cell count and differential [1] Hemo globin 
Red blood cell coun t Mean corpuscular volume 
Platelets Mean corpuscular hemo globin 
Hematocrit Mean corpuscular hemo globin concentration 
Prothrombin time  Partial thromboplastin time  
Vitamin B12 
1. Manual microscopic review is performed only if white blood cell count and/or differential values are out of 
reference range. 
Immunochemistry 
Thyroid Function [T4, T4 (Free), T3, T3 (Free), TSH] 
Syphilis 
Endocrinology 
Follicle-stimulating hormone [1]   
1. Follicle-stimulating hormone in in peri-menopausal (irregular menstrual periods) or post-menopausal (no 
menstrual period for >12 months) female subjects at screening.  
 
Serology 
Hepatitis B surface anti gen Hepatitis C virus antibodies 
Human immunodeficiency virus 1 and 2 
antibodies  
 
Urinalysis 
Bilirubin Blood Glucose Ketones 
Leukoc
yte esterase Microscop y [1] 
Nitrite pH 
Protein Specific gravity 
Urobilino gen  
1. Microscopy will be performed only as needed based on positive dipstick test results.  
Protocol COR388-010  Version 7.0 Page 84 
17 May 2021 
Cortexyme, Inc.  Confidential Information APPENDIX A: CLINICAL LABORATORY ANALYTES  (CONTINUED) 
Drug Screen 
Opi[INVESTIGATOR_33302] y AD biomarkers  
DNA = deoxyribonucleic acid; qPCR = quantitative polymerase chain reaction.  
Saliva/Oral Fluids Biomarkers- 
Porphyromonas gingivalis and oral microbiome 
DNA qPCR and biomarkers  
DNA = deoxyribonucleic acid; qPCR = quantitative polymerase chain reaction.  
Blood Biomarkers 
Porphyromonas gingivalis  biomarkers in serum 
and PBMCs  
Neuroinflammator y markers 
PBMCs = Peripheral blood mononuclear cells.  
Liver Safety Monitoring
Alanine transaminase 
Aspartate transaminase 
Gamma-glutamyl transferase 
Alkaline Phosphatase Total Bilirubin Direct bilirubin Indirect bilirubin 
Eosinophils (% and Abs) 
Prothrombin Time as INR 
Extended Liver Safety Testing for AST or ALT >3x ULN 
INR 
Direct bilirubin 
Auto-antibodies 
Bile salts/acids 
Cytom
egalovirus 
Epstein-Barr viru s 
Herpes sim p lex virus 
Anti-nuclear antibodi es 
Anti-smooth muscle antibodies  
Immuno
globulin G 
See liver safety monitoring procedures in Section 8.24 